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24h-ABPM: 24 hours – ambulatory blood pressure monitoring  
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II_L: late phase II of the Valsalva maneuver 
ANS: autonomic nervous system 
BP: blood pressure (sysBP: systolic blood pressure; diaBP: diastolic blood pressure) 
DLB: Dementia with Lewy bodies 
HR: heart rate 
OH: orthostatic hypotension 
MSA-C: multiple system atrophy – cerebellar 
MSA-P: multiple system atrophy – parkinsonian 
PAF: pure autonomic failure 
PD: Parkinson’s disease 
PDD: Parkinson’s disease with dementia 
SH: supine hypertension 
WMH: white matter hyperintensities 
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1. Introduction 
1.1. A two-players game 
1.1.1. Player #1: the autonomic nervous system 
The Autonomic Nervous System (ANS) mediates neuroendocrine, visceral and behavioural 
responses to environmental and inner challenges in order to ensure body homeostasis. 
The insular cortex, together with the medial prefrontal cortex and the extended 
amygdala, exerts high-order autonomic control on multiple parallel pathways of the ANS 
subcortical integrative network. This is constituted by the hypothalamus, periacqueductal 
grey matter, parabrachial pontine complex and ventro-lateral medullary nuclei 
(Benarroch, 1993). Main output of the central ANS runs through pre-ganglionic 
sympathetic and parasympathetic cholinergic neurons, the former located in the 
intermediolateral columns of the thoraco-lumbar spinal cord, the latter in the brainstem 
and sacral spinal myelomera. Parasympathetic cholinergic post-ganglionic fibers arise 
from ganglia which are generally located close or within the target organ. Activation of 
vagal parasympathetic fibers to the atrial sinus node induces bradycardia. Noradrenergic 
sympathetic post-ganglionic neurons originate from the paravertebral ganglia and 
mediate blood vessel constriction, positive inotropic and chronotropic cardiac effects 
among others (Goldstein, 2006).  
Short-term regulation of blood pressure (BP) and heart rate (HR) is committed to the 
baroreflex arch, which modulates sympathetic and parasympathetic activation in order to 
ensure appropriate organ perfusion under postural and blood volume changes. If arterial 
BP falls, mechanical baroreceptors situated in the carotid sinus and aortic arch 
contemporarily inhibit vagal input to the sinus node and promote sympathetic outflow to 
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cardiac fibers and blood vessels. As the result, heart rate, heart inotropism and vascular 
peripheral resistances increase. If arterial BP rises, the opposite occurs: cardiovagal 
activation induces bradycardia, while inhibition of sympathetic fibers produces negative 
inotropic effects and blood vessel relaxation (Freeman, 2008). 
Fig.  1.1 The baroreflex arch 
 
PVN: paraventricular nucleus (hypothalamus); SON: sopraoptic nucleus, hypothalamus; RVLM: rostral 
ventrolateral medulla; CVLM: caudal ventrolateral medulla; NTS: nucleus of the tractus solitaries (vagus 
nerve); NA: nucleus ambiguous (vagus nerve). Reproduced from Freeman R (2008), NEJM; 358 (6): 615-624 
with permission from the Massachusetts Medical Society. 
 
Disorders of the ANS are classified as primary, if due to neurodegeneration, or secondary, 
if developing after brain injury, intoxication or metabolic diseases such as diabetes 
mellitus. The first report of degenerative autonomic failure dates back to 1925 when 
Bradbury and Egglestone described a case of orthostatic hypotension (OH) with 
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impotence and anhidrosis of idiopathic origin (Bradbury S, 1925). In the 60s of the past 
century Shy and Drager further reported the case of two men who developed multi-
domain autonomic failure along with cerebellar, parkinsonian and pyramidal signs (Shy 
and Drager, 1960). Since then, autonomic failure has been recognized as major non-
motor feature of multiple system atrophy (MSA), Parkinson’s disease (PD) as well as other 
movement disorders (Wenning, 2013) with prominent diagnostic, therapeutic and 
prognostic implications. 
 
1.1.2. Player #2: -synucleinopathies 
PD is an adult-onset neurodegenerative disease characterized by bradykinesia and a 
combination of rest tremor, rigidity and postural instability (Hughes et al., 2001). 
Neuropathological hallmark of PD are the Lewy bodies, neuronal aggregates of misfolded 
-synuclein developing in the central, peripheral as well as enteric nervous system (Braak 
et al., 2003). Throughout disease course, PD patients additionally develop a wide 
spectrum of non-motor symptoms, including autonomic, behavioural and cognitive 
changes (Barone et al., 2009), sometimes achieving a diagnosis of PD with dementia 
(PDD) in advanced stages.  
MSA is an adult-onset, fatal neurodegenerative disease presenting with progressive 
autonomic failure, parkinsonian, cerebellar and pyramidal features in various 
combinations. It is classified as MSA-parkinsonian (MSA-P), if parkinsonism prevails, or 
MSA-cerebellar (MSA-C), if cerebellar features predominate. Proteinaceous 
oligodendroglial cytoplasmic inclusions (also known as Papp-Lantos bodies) are the 
hallmark of MSA. The main constituent of glial cytoplasmic inclusions is misfolded α-
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synuclein, hence classifying MSA as an oligodendroglial α-synucleinopathy. As in PD, a 
considerable variety of non-motor symptoms may develop during MSA disease course 
and sometimes even precede development of motor symptoms (Jecmenica-Lukic et al., 
2012). Multi-domain autonomic failure, including urogenital, cardiovascular, 
gastrointestinal and thermoregulatory dysfunction invariably occurs in almost all patients 
(Fanciulli A, 2014) and significantly affects quality of life in MSA (Schrag et al., 2006). 
 
1.2. Focus on cardiovascular autonomic failure in PD and MSA 
1.2.1. Clinical features and epidemiology 
Cardiovascular autonomic failure is a common dysautonomic symptom in PD (Barone et 
al., 2009) and a mandatory criterion for the diagnosis of MSA (Gilman et al., 2008). 
The main feature of cardiovascular autonomic failure is orthostatic hypotension (OH) 
(Asahina et al., 2012). OH is defined as a of systolic blood pressure (sysBP) fall ≥ 20 mmHg 
or diastolic (diaBP) ≥ 10 mmHg within 3 min of active standing or head-up tilt. In case of 
supine hypertension, a sysBP fall ≥ 30 mmHg is considered a more appropriate criterion 
for the diagnosis of OH. OH may manifest with recurrent syncope, light-headedness, 
weakness, nausea, fatigue, headache or shoulder-neck pain upon standing, but may also 
lack any symptomatology (Freeman et al., 2011). Frequency rates of OH in PD range from 
14-15% in drug-naïve and early-stage patients (Bonuccelli et al., 2003, Barone et al., 2009) 
to 52% in more advanced and older cases, on higher dopaminergic drug dosage and 
showing gait unbalance (Allcock et al., 2006, Matinolli et al., 2009, Velseboer et al., 2011). 
Symptomatic OH occurs in 50% of MSA patients already in early disease stages 
(Sakakibara et al., 2000), with peak cross-sectional prevalence of 75% and 81% in 
A. Fanciulli - Cardiovascular autonomic failure in PD and MSA 
 
 
13 
European and American cohorts (Kollensperger et al., 2010, Ha et al., 2011). One cross-
sectional study reported OH to be more frequent and severe in patients with MSA-C than 
with MSA-P (Wenning et al., 2012). 
Attending phenomena of OH are supine hypertension, nocturnal hypertension with 
reversal of physiological BP circadian rhythm, and postprandial hypotension. Supine 
hypertension is usually asymptomatic or only manifest with vague complaints. It has been 
reported in approximately 50% of MSA patients with overt OH (Shannon et al., 1997, 
Biaggioni and Robertson, 2002), while no former study is available on the prevalence of 
supine hypertension in the setting of PD. Notably, no homogeneous cut-off values were 
used for the diagnosis of supine hypertension in the above mentioned papers (Schutzman 
et al., 1994, Shannon et al., 1997, Jordan et al., 1999).  
Specific cut-off values for the diagnosis of nocturnal hypertension in patients suffering 
from cardiovascular autonomic failure are also missing. Current consensus guidelines for 
the general population define two main pathological nocturnal BP profiles, named 
respectively as non-dipping and reverse dipping (Staessen et al., 2001). A non-dipping 
profile is characterized by a nocturnal BP reduction lower than 10% with respect to 
daytime values, whereas a reverse dipping occurs if BP increases during night time 
(Staessen et al., 2001). Loss of physiological nocturnal blood pressure fall has been 
reported in 48% of PD and 68% of MSA patients (Schmidt et al., 2009). It may be even 
more frequent in patients with severe cardiovascular autonomic failure (Plaschke et al., 
1998), or in older and more advanced cases (Berganzo et al., 2013), but, since almost 
asymptomatic, it is frequently underdiagnosed and undertreated. 
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1.2.2. Clinical investigation of cardiovascular autonomic function  
Bedside screening of cardiovascular autonomic failure can be run by mean of a simple 
standing test (also known as Schellong’s test): during this test, the patient is asked to lie 
for 5 to 10 minutes and then to stand up for 5 minutes. Oscillometric BP is recorded at 
the end of the supine phase and at 3 and 5 minutes after standing. If the test shows 
supine hypertension and/or OH (Freeman et al., 2011), further investigation is 
recommended. Continuous heart rate (HR) and BP monitoring by means of non-invasive 
beat-to-beat BP recording and impedance cardiography (i.e. Task Force® Monitor or 
Finapres® devices) allows evaluation of cardiovascular autonomic function during 
provocative testing. Standard test procedures include passive head-up tilting at 60°, 
active standing, the Valsalva maneuver and the deep breathing test. Previous studies 
reported OH to occur more frequently during passive head-up tilt than active standing 
and often after the standard time cut-off of 3 minutes (Jamnadas-Khoda et al., 2009). For 
this reason, both passive and active orthostatic challenges are routinely performed and 
examination time extended up to 10 minutes.  
Finally, 24h ambulatory BP monitoring should be included in the initial evaluation of 
cardiovascular autonomic failure to detect supine and nocturnal hypertension attending 
OH, since latter phenomena are frequently asymptomatic or only manifest with unspecific 
symptomatology. 
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Fig.  1.2 Co-occurrence of supine hypertension (*) and OH (**) at head-up tilt test.  
 
 
A. parkinsonian patients; B. Healthy control. Fanciulli et al., unpublished material 
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Fig.  1.3 Possible nocturnal BP profiles at 24h – ambulatory BP monitoring 
 
A – Dipping (BP falls ≥10% with respect to daytime); B – Non-dipping (BP falls <10% with respect to 
daytime); C Reverse-dipping (BP increases with respect to daytime). Note the presence of post-prandial 
hypotension in profile C at 1:00 and 8:00 p.m. Reproduced from Fanciulli et al. (2014), Journal of Neurology; 
261 (7): 1291-9 with permission from Springer Verlag GmbH. 
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1.2.3. Pathophysiology of cardiovascular autonomic failure in PD and MSA 
The synergism between degeneration of sympathetic post-ganglionic fibers to the heart 
and blood vessels and baroreflex failure underlies the development of OH attending PD. 
Lewy bodies accumulating in distal axons of peripheral sympathetic neurons contribute to 
degeneration of sympathetic fibers first and subsequently drive retrograde neuronal 
death in the paravertebral ganglia (Orimo et al., 2008). As the result, PD patients show 
low plasma noradrenaline levels while lying, which fail to rise appropriately under 
orthostatic challenge (Goldstein et al., 2003) 
Conversely, degeneration of autonomic preganglionic fibers represents the primary site of 
autonomic failure in MSA. Studies carried out by different research groups confirmed the 
significant relationship between degeneration of medullary intermediolateral columns 
and occurrence of cardiovascular autonomic failure in the disease (Papp and Lantos, 
1994, Wenning et al., 1997). Neurodegenerative changes have been also shown in the 
nucleus ambiguus of the vagus nerve and in catecholaminergic neurons of the 
ventrolateral medulla at post-mortem pathology of definite MSA cases, possibly 
explaining the more severe degree of autonomic failure observed in the disease 
(Benarroch, 2003, Benarroch et al., 2006). In contrast to PD, MSA patients show normal 
or only minimally lowered plasma noradrenaline levels when supine, but almost missing 
increase of plasma noradrenaline concentration while standing (Goldstein et al., 2003). 
The pathophysiology of supine and nocturnal hypertension in the context of autonomic 
failure is unclear at present. Patients suffering from OH often develop peripheral edema 
due to insufficient residual hydrostatic venous pressure. During night time, a counter fluid 
shift from extracellular compartment into the vascular bed may occur, resulting in blood 
volume expansion and nocturnal hypertension (Plaschke et al., 1998). An alternative 
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explanation is provided by the so-called “vasoconstriction model”. According to this 
model, MSA patients suffering from OH may develop a denervation-dependant 
hypersensitivity of vascular α-adrenoceptors as an attempt to shelter themselves from 
excessive BP falls upon standing. In turn, the same hypersensitivity may produce 
exaggerated vasoconstrictor responses to tonic sympathetic stimulation while lying, 
which cannot be modulated due to impaired central autonomic pathways (Davies et al., 
1982). It is, however, unclear if this same explanatory model can justify the occurrence of 
supine hypertension in PD, since PD patients show lowered plasmatic noradrenaline 
levels in the upright as well supine position. 
 
1.2.4. Orthostatic hypotension: principles of treatment 
Orthostatic hypotension has been shown to significantly affect quality of life and activity 
of daily living in parkinsonian subjects (Colosimo et al, 2010). A multidimensional 
approach, with combined pharmacological and non-pharmacological measures is to be 
pursued in order to warrant best clinical management of dysautonomic symptoms in 
movement disorders (Mostile and Jankovic, 2009). 
Non-pharmacological measures include avoiding OH-triggers such as rapid postural 
change, heavy meals, straining while coughing or passing stool, and exposure to hot 
temperature. If patients feel light-headed (dizzy), physical counter maneuvers like 
crossing legs, squatting or tensing muscles, may prevent syncope. Other non-
pharmacological measures to ameliorate OH include increased water and salt intake, 
head-up tilt during sleep, compression stockings or abdominal binders (Freeman, 2008). If 
severe OH occurs, pharmacological measures are advisable to minimize the risk of 
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injurious falls. Drugs with hypotensive side-effects (e.g. anti-hypertensive medications, 
anti-anginal agents, 1-adrenoreceptor antagonists for the treatment of prostatic 
hypertrophy) should be avoided or at least administered in the evening. Midodrine and 
droxidopa, sympathomimetic agents that increase arteriolar tone, are specifically licensed 
by the Food and Drug Administration for the symptomatic treatment of neurogenic 
orthostatic hypotension (Jankovic et al., 1993, Low et al., 1997, Wright et al., 1998, 
Freeman et al., 1999). Off-label administration of fludrocortisone can be helpful in 
addition to increase the intravascular volume (Chobanian et al., 1979). Beneficial effects 
have also been reported for ephedrine, pseudoephedrine, piridostigmine, desmopressin 
and erythropoietin used off-label in orthostatic hypotension associated with autonomic 
failure (Fouad-Tarazi et al., 1995, Perera et al., 1995, Jordan et al., 1998, Sakakibara et al., 
2003, Singer et al., 2003).  
Notably, most of the available evidences for the management of cardiovascular 
autonomic failure have been collected in cohorts with OH of different etiologies. 
Recently, an EBM-review endorsed from the International Parkinson Disease and 
Movement Disorder Society found that current evidence is not sufficient to conclude on 
safety and efficacy of currently available pharmacological options in the setting of PD and 
therefore classified their use as investigational (Seppi et al., 2011). Due to limited 
literature availability, no similar EBM-review has been ever performed for the non-
pharmacological management of OH either in PD or in MSA. 
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1.2.5. Prognostic impact of cardiovascular autonomic failure: evidence from the 
general population 
Prospective epidemiological studies in the general population highlighted that OH 
represents a negative prognostic factor for mid-term and long-term survival in elderly 
people (Masaki et al., 1998, Rose et al., 2006). OH has been associated with an increased 
risk of major cardiovascular events (Rose et al., 2000, Luukinen et al., 2004, Rose et al., 
2006, Fagard and De Cort, 2010), future development of heart failure (Fedorowski et al., 
2010),  hypertension and shifting to non-dipping or even reversal nocturnal BP profile 
(Rose et al., 2002, Fagard and De Cort, 2010). OH and nocturnal hypertension have been 
also shown to predict major cerebrovascular events on a 5.5 to 7.9 year follow-up period 
(Eigenbrodt et al., 2000, Iqbal and Stevenson, 2010) and to represent a major risk factors 
for brain subcortical white matter hyperintensities (WMH) in the elderly (de Leeuw et al., 
2002, Goldstein et al., 2005, Murray et al., 2005, Ma et al., 2010). 
It is still debated whether OH represents a risk factor for cognitive impairment in the 
general population. In the middle-aged to elderly independently living population, OH 
does not seem to correlate neither to predict future cognitive impairment at 2- to 6-year 
follow-up (Viramo et al., 1999, Yap et al., 2008, Rose et al., 2010), whereas in older 
people attending memory clinics, OH has been associated with decreased verbal memory, 
reduced concentration ability, and a 2.19 hazard ratio of developing cognitive impairment 
over a 7-year follow-up time (Elmstahl and Rosen, 1997, Verghese et al., 2003, 
Czajkowska et al., 2010, Mehrabian et al., 2010). Other studies showed a strong 
association between cognitive impairment and supine/nocturnal hypertension in the 
general population (Kuo et al., 2004, Yano et al., 2011), with WMH possibly representing 
the etiological link between these two phenomena (Matsubayashi et al., 1997).  
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It is unclear at present which role does cardiovascular autonomic failure exert on survival, 
cardiovascular and cognitive outcome in the setting of -synucleinopathies. 
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2. Research plan 
The above described clinical scenario depicts several unmet needs concerning 
cardiovascular autonomic failure in the field of PD and MSA.  
Up to date it is not clear whether features of cardiovascular autonomic failure like OH, 
supine and nocturnal hypertension have a negative prognostic impact in -
synucleinopathies like they do in the general population. Further, the occurrence of 
nocturnal hypertension remains largely underdiagnosed in the routine management of 
parkinsonian patients and the actual prevalence of supine hypertension in PD and MSA 
diagnosed according to the most recent international criteria hasn’t been investigated 
yet. Finally, few randomized controlled trials have been run for the non-pharmacological 
management of OH in PD. 
Given these premises, a 4-step research plan has been developed, the results of which 
will be discussed in the present dissertation. First, a systematic review of the literature 
has been run to evaluate the prognostic role of cardiovascular autonomic failure on 
survival, cardiovascular, cerebrovascular and cognitive outcome in -synucleinopathies. 
In a second phase, a cross-sectional cohort has been enrolled to develop a screening 
algorithm to detect nocturnal hypertension in PD and MSA on the basis of standard tilt-
test evaluations. In a third step, a large retrospective cohort of PD and MSA patients has 
been recruited thanks to the collaboration of the Innsbruck and Rome Parkinson equips 
with the aim of investigating the prevalence of supine hypertension in parkinsonian 
patients according to the American Heart Association consensus criteria (Chobanian et al., 
2003). Fourth, a randomized, placebo-controlled, cross-over trial, followed by a 4-weeks 
open-label phase has been performed to evaluate the efficacy of elastic abdominal 
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binders in reducing orthostatic blood pressure fall upon tilting and OH-related 
symptomatic burden in daily living in PD patients suffering from OH. 
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Hereunder we report an excerpt of the study. Full-text of the related article can be found 
at: 
http://www.ncbi.nlm.nih.gov/pubmed/22834919 
 
3.1. Background 
In contrast with prior belief of protective effects from low BP values, recent studies 
highlighted the negative prognostic role of cardiovascular autonomic failure on 
cardiovascular and cerebrovascular outcomes, as well as mid-term and long-term 
mortality in the general population. Symptoms of cardiovascular autonomic failure 
including OH, supine and nocturnal hypertension may affect more than half of 
parkinsonian patients already from disease beginning. It is up to date unclear whether 
such symptoms have a similar negative impact in -synucleinopathies.  
3.2. Aim 
Here we provide a systematic review of cardiovascular autonomic failure in α-
synucleinopathies, focusing on its impact on survival, cardio-, cerebrovascular and 
cognitive outcome in PD and MSA.  
3.3. Methods 
A PubMed database search was performed using the keyword-based method indicated in 
Table 3.1. Studies with a retrospective, cross-sectional or prospective design as well as 
case reports assessing survival, cardiovascular, cerebrovascular and cognitive outcomes 
were analysed. Articles were restricted to the English language and spanned the period 
between January 1985 and April 2012. For the purposes of the present dissertation a 
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renewed PubMed search was run after the same criteria to include studies published until 
October 2014. 
Table 3.1 Key-words based PubMed search 
 
“Multiple system atrophy” 
OR 
“Parkinson’s disease” 
OR 
“Parkinson’s disease with dementia” 
OR 
“Dementia with Lewy bodies” 
OR  
“Pure autonomic failure” 
 
 
AND 
 
 “orthostatic hypotension” 
 “cardiovascular autonomic 
failure” 
 “cardiovascular dysautonomia” 
 “neurocardiovascular instability” 
 “supine hypertension” 
 “recumbent hypertension” 
 “nocturnal hypertension” 
 
3.4. Results 
The systematic search identified 25 studies, the main characteristics of which are 
summarized in Table 3.2.  
In MSA, early development of autonomic failure, in particular of cardiovascular and 
urological type, predicted faster disease progression and shorter interval from onset to 
death (Watanabe et al., 2002, Tada et al., 2007, O'Sullivan et al., 2008). In a mirror 
fashion, all case reports of MSA patients with prolonged survival were characterized by 
late-onset cardiovascular autonomic failure (Petrovic et al., 2012, Calandra-Buonaura et 
al., 2013). Contrasting evidence is available for PD. While OH did not represent an 
independent predictor of death in a cohort of newly diagnosed PD patients at 10-years 
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follow-up (Auyeung et al., 2012), this was instead the case for PD patients with long 
disease duration (Cilia et al., 2014) or superimposing dementia (Stubendorff et al., 2012).  
No study assessing the influence of autonomic failure on cardiovascular outcome in 
exclusively MSA or PD cohorts is available. An association between autonomic failure and 
left ventricular hypertrophy was found in mixed cohorts including PD and MSA patients 
(Vagaonescu et al., 2000, Maule et al., 2006, Maule et al., 2012). 
Epidemiological studies showed an increased prevalence of stroke and cerebrovascular 
mortality in PD, but due to their retrospective nature, a case-selection bias cannot be 
excluded (Gorell et al., 1994). In PD, an association among OH, supine hypertension and 
cerebral subcortical ischemic damage was found in two studies (Oh et al., 2013), but 
rebutted in a third one (Pilleri et al., 2013). Notably, different methodologies were 
applied for the assessment of white matter hyperintensities (WMH) at MR scanning and 
duration of cardiovascular autonomic failure was not included as covariate in the 
statistical analysis of the above mentioned studies. Two studies from different research 
groups reported an association between severity of OH and supine hypertension and 
WMH burden in MSA (Lim et al., 2009, Tha et al., 2010). 
A significant relationship between diverse cognitive deficits, OH and supine hypertension 
has been found in six out of seven cross-sectional studies in PD cohorts (Allcock et al., 
2006, Idiaquez et al., 2007, Peralta et al., 2007, Hohler et al., 2012, Kim et al., 2012, Pilleri 
et al., 2013, Jones et al., 2014). Finally, although overt dementia is an exclusion criterion 
for the diagnosis of MSA (Gilman et al., 2008), minor degrees of cognitive impairment 
(especially in executive tasks) have been reported in this disease and significantly related 
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to the occurrence of cardiovascular autonomic failure (Deguchi et al., 2001, Brown et al., 
2010).  
Table 3.2 Prognostic impact of cardiovascular autonomic failure in PD and MSA: an overview 
per domain.  
Author Sample size (n) Study design Outcome 
Survival     
(Cilia et al., 2014)* 401 PD Retrospective, 
cross-sectional, 
prospective 
In patients with longer disease 
duration (>20 years) mortality is 
associated with male gender, older 
age, dysphagia, OH, postural instability, 
fractures and institutionalization 
(Auyeung et al., 2012)* 171 PD Retrospective OH is not an independent predictor of 
death at 10-years follow-up 
(Stubendorff et al., 
2012)* 
30 PDD/DLB Prospective Persistent OH is associated with 
shorter survival a 3-years follow up 
(Calandra-Buonaura et 
al., 2013)* 
5 MSA Prospective Prolonged survival is associated with 
late onset of OH and urinary voiding 
symptoms 
(Petrovic et al., 2012)* 4 MSA Retrospective Late appearance of dysautonomia is a 
favorable prognostic factor in MSA-P. 
(O'Sullivan et al., 2008) 83 MSA Retrospective Early autonomic failure is associated 
with 6x increased risk of death 
(Tada et al., 2007) 49 MSA Retrospective Precocious autonomic failure (<2.5 
years within disease onset) predicts 
higher disability, worse prognosis and 
sudden death 
(Watanabe et al., 
2002) 
230 MSA Retrospective Concomitant motor and autonomic 
involvement within 3 years of onset is 
associated with faster disease 
progression and worse prognosis 
Cardiovascular 
outcome 
   
(Maule et al., 2012)* 45 PD and 43 MSA 
with OH 
Retrospective 51% prevalence of cardiovascular 
comorbidities (hypertension, angina, 
atrial fibrillation, heart failure) 
(Vagaonescu et al., 
2000) 
6 PAF, 8 MSA, 12 
hypertensives, 14 
Cross-sectional Left-ventricular mass index in patients 
with autonomic failure is as high as in 
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Author Sample size (n) Study design Outcome 
controls hypertensives. 
(Maule et al., 2006) 25 patients with 
autonomic failure, 20 
hypertensives 
Cross-sectional Left-ventricular hypertrophy positively 
correlates with high BP 24-h variability 
in autonomic failure. 
Cerebrovascular 
outcome 
   
(Oh et al., 2013)* 117 PD Cross-sectional Both supine hypertension and OH 
predict higher WMH burden 
(Pilleri et al., 2013)* 48 PD Cross-sectional No difference in subcortical ischemic 
load between PD patients with and 
without OH 
(Kim et al., 2012)* 87 PD Cross-sectional WMH burden correlated with 
orthostatic diastolic BP fall 
(Gorell et al., 1994) 8629 PD, 208933 
controls 
Retrospective PD patients are more likely to die from 
cerebrovascular causes than the 
general population 
(Tha et al., 2010) 16 MSA, 16 controls Cross-sectional OH severity correlates with supra- and 
infratentorial white matter 
abnormalities in MSA. 
(Lim et al., 2009) 63 MSA, 63 controls Cross-sectional Supine hypertension is a major 
predictor of WMH severity in MSA. 
Cognitive outcome    
(Jones et al., 2014)* 341 PD Cross-sectional Hypertension, and to a lesser extent 
OH, are significantly associated with 
frontal executive dysfunction and 
impaired verbal memory 
(Pilleri et al., 2013)* 48 PD Cross-sectional OH is associated with worse cognitive 
performance (sustained attention, 
visuospatial, verbal memory) in PD 
(Kim et al., 2012)* 87 PD Cross-sectional Cognitive impairment is associated 
with the co-occurrence of supine 
hypertension and OH. 
(Hohler et al., 2012)* 44 PD Cross-sectional OH is associated with lower motor and 
cognitive performance 
(Allcock et al., 2006) 175 PD Cross-sectional PD patients with OH show significant 
impairment in sustained attention and 
visual episodic memory. 
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Author Sample size (n) Study design Outcome 
(Peralta et al., 2007) 10 PD, 8 PDD Cross-sectional OH exacerbates attentional 
dysfunction in PDD patients. 
(Idiaquez et al., 2007) 40 PD, 30 controls Cross-sectional OH does not correlate with the severity 
of cognitive impairment in PD cases. 
(Kitayama et al., 2008) 95 PD Cross-sectional Cardiac 
123
I-MIBG signal reduction is 
more severe in hallucinated and 
demented PD patients. 
(Brown et al., 2010) 372 MSA Cross-sectional In MSA, cardiovascular dysautonomia is 
predictive of cognitive impairment. 
(Deguchi et al., 2001) 9 MSA, 9 controls Cross-sectional Frontal lobe dysfunction positively 
correlates with systolic BP drop upon 
standing. 
 
*: studies available after publication of the review in 2012. DLB: dementia with Lewy 
bodies; OH: orthostatic hypotension; MIBG: metaiodobenzylguanidine; PAF: pure 
autonomic failure; PDD: Parkinson’s disease with dementia; WMH: white matter 
hyperintensities 
 
3.5. Discussion 
Current evidence underscores an association between cardiovascular autonomic failure 
and mortality in MSA and PD, especially in older and demented patients. Cardiovascular 
autonomic failure may indeed induce potentially life-threatening events like syncope and 
injurious falls. Alternatively, development of cardiovascular autonomic failure may reflect 
a more severe disruption of brainstem cardio-respiratory drive which may, in turn, 
increase the risk of sudden death in MSA.  
Altered cerebral perfusion, vascular pressure stress, and related disruption of the blood-
brain barrier may contribute to the subcortical ischemic damage and cognitive 
dysfunction frequently found in patients affected by cardiovascular autonomic failure, 
with duration and severity of BP disruption possibly playing a pivotal role. On the other 
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hand, OH and cognitive impairment may result from neurodegenerative changes affecting 
areas involved in both cognition and cardiovascular autonomic control like the anterior 
cingulate cortex (Poewe, 2007).  
3.6. Conclusion 
Current evidence supports the hypothesis that cardiovascular autonomic failure may play 
a negative prognostic role in PD and MSA and suggest that precocious screening and 
therapeutic management of cardiovascular autonomic failure may positively influence 
disease outcome and quality of life in -synucleinopathies. 
 
A. Fanciulli - Cardiovascular autonomic failure in PD and MSA 
 
 
32 
4. Detecting nocturnal hypertension in Parkinson’s disease and multiple 
system atrophy: proposal of a decision-support algorithm 
Alessandra Fanciulli  MD1,2, Stefano Strano MD3, Jean Pierre Ndayisaba MSc2, 
Georg Goebel PhD4, Laura Gioffrè MD3, Massimiliano Rizzo MD3, Carlo 
Colosimo MD5, Carlo Caltagirone MD6, Werner Poewe MD2,  
Gregor K. Wenning MD PhD MSc2*, Francesco E. Pontieri MD1,6* 
1
Department of Neuroscience, Mental Health and Sensory Organs, "Sapienza” University of Rome, Italy 
2
Department of Neurology, Innsbruck Medical University, Austria 
3
 Department of Heart and Great Vessels “A. Reale”, "Sapienza” University of Rome, Italy 
4
Department of Medical Statistics, Informatics and Health Economics, Innsbruck Medical University, Austria 
5
 Department of Neurology and Psychiatry, “Sapienza” University of Rome, Italy 
6 
I.R.C.C.S Santa Lucia Foundation, Rome Italy 
*These authors contributed equally to the work 
 
 
 
Authors’ contributions 
Research conception: AF, SS, CCa, WP, GKW, FEP; research organization: AF, SS, CCo, 
GKW, FEP; research execution: AF, SS, JPN, LG, MR, CCo, FEP 
Statistical design: AF, GG, GKW, FEP; statistical analysis: AF, GG, JPN; data review and 
critique: GG, SS, WP, GKW, FEP 
Writing of the first draft: AF 
Critical revision of the manuscript: SS, JPN, GG, MR, LG, CCa, CCo, WP, GKW, FEP 
Approval of the final version of the manuscript: AF, SS, JPN, GG, MR, LG, CCa, CCo, WP, 
GKW, FEP
A. Fanciulli - Cardiovascular autonomic failure in PD and MSA 
 
 
33 
Hereunder we report an excerpt of the study. Full-text of the related article can be found 
at: 
http://link.springer.com/article/10.1007%2Fs00415-014-7339-2 
 
4.1. Background 
A pathological nocturnal blood pressure (BP) profile, either non-dipping or reverse-
dipping, occurs in more than 50% of subjects diagnosed with multiple system atrophy 
(MSA) or Parkinson’s disease (PD). This may play a negative prognostic role in α-
synucleinopathies, but, being mostly asymptomatic, remains largely underdiagnosed.  
4.2. Aim 
In this proof-of-concept cross-sectional study, we aimed at developing a decision-support 
algorithm to predict pathological nocturnal BP profiles during a standard tilt-table 
examination in PD and MSA. 
4.3. Methods 
Sixteen MSA and sixteen PD patients underwent standard tilt-table examination and 24h-
ambulatory BP monitoring (24h-ABPM). Clinical and tilt-test differences between patients 
with a normal (dipping) and a pathological (non-dipping or reverse-dipping) nocturnal BP 
profile at 24h-ABPM were assessed applying the Mann-Whitney U test for quantitative 
variables, and Pearson’s Χ2 test (or the Fisher’s exact test, where appropriate) for 
categorical variables. Tilt-table parameters displaying the most significant difference 
between the normal and pathological nocturnal BP group were selected and a regression 
tree algorithm (CART) with 5-fold cross-validation methodology was developed to predict 
a pathological nocturnal BP profile in PD and MSA. 
A. Fanciulli - Cardiovascular autonomic failure in PD and MSA 
 
 
34 
4.4. Results 
75% of MSA (37, 5% non-dippers, 37, 5% reverse-dippers) and 31% of PD (25% non-
dippers, 6% reverse-dippers) patients showed a pathological nocturnal BP profile. A 
significant association between MSA diagnosis and a pathological nocturnal BP profile 
was observed (p=0.032), but not between pathological nocturnal BP profiles and gender, 
age, disease stage/duration, L-dopa equivalent daily dosage or use of anti-hypotensive 
medications (seeTable 4.1).  At tilt-test examination, pathological nocturnal BP profiles 
were associated with greater systolic/diastolic BP drop after 3 minutes of head-up tilting 
(p=0, 03), joint occurrence of orthostatic hypotension and supine hypertension (p=0, 03), 
and lack of the physiological BP overshoot in the late phase II (II_L, p=0, 002) and in the 
phase IV (p=0, 007) of the Valsalva maneuver (see Table 4.1). Combined ∆ BP ≤ 0,5 mmHg 
in the II_L and ≤ -7 mmHg in the IV phase of Valsalva manoeuvre, correctly predicted a 
pathological nocturnal BP profile at 24h-ABPM with 87,5% sensitivity and 85,7% 
specificity (see Fig. 4.1 and Fig. 4.2). 
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Table 4.1 Clinical and tilt test associations of nocturnal BP profiles (normal vs. non-dipping & 
reverse-dipping) in PD and MSA 
 Normal nocturnal BP 
profile 
Pathological nocturnal BP 
profile 
p 
Clinical features    
N 15 17 - 
Neurological diagnosis, MSA: PD (%) 4: 11 (27: 73) 12: 5 (71: 29) 0.032 
Sex, female: male (%) 6: 9 (40: 60) 3: 14 (18: 82) 0,243 
Age (yr) 65 (60; 69) 68 (60; 76) 0,737 
Disease duration (yr) 4 (3; 5) 6 (3; 8) 0,082 
Hoehn & Yahr Stage  2.5 (2; 3) 3 (2.5; 4) 0,058 
L-dopa equivalent daily dose (mg) 505 (305; 680) 358 (270; 1015) 0,576 
Anti-hypotensive medications, n (%) 0 (0) 3 (18) 0,229 
Anti-hypertensive medications, n (%) 3 (20) 9 (53) 0,076 
    
Tilt-test parameters    
Supine sys BP (mmHg) 124 (120; 131) 115 (99; 136) 0,551 
Supine dia BP (mmHg) 79 (69; 84) 70 (63; 85) 0,551 
∆ sys BP after 3 min tilting (mmHg) 4 (-16; +12) -22 (-35; +10) 0.03 
∆ dia BP after 3 min tilting (mmHg) 7 (-1; +9) -7 (-22; +6) 0.027 
SH, n (%) 3 (20) 5 (29) 0,691 
OH, n (%) 1 (7) 11 (65) 0.001 
OH only, n (%) 1 (7) 6 (35) 0,088 
SH only, n (%) 3 (20) 0 (0) 0,092 
SH+OH, n (%) 0 (0) 5 (29) 0.046 
∆ BP Valsalva II_L (II_L-II_E), (mmHg)  1 (-6; +18) -7 (-12; -2) 0.002 
∆ BP Valsalva IV (IV-I), (mmHg)  -4 (-10; +7) -11 (-16; -8) 0.007 
Ewing’s Score (sum of pathological 
Ewing’s tests)  
0 (0;1) 1 (0; 2) 0,089 
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Fig. 4.1 Heart rate (HR) and BP behaviour during Valsalva maneuver, phase I to IV. A: normal 
finding, with BP overshoots in phase II_L and phase IV (arrows).  B: pathological finding, with BP 
falls in phase II_L and phase IV 
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Fig. 4.2 Two-step decision-support algorithm to predict a pathological nocturnal BP profile in PD 
and MSA. During the execution of the Valsalva maneuver, measure mean BP values achieved at 
the end of phase I, II_E, II_L and IV (see Fig. 4.1 for detailed description of Valsalva maneuver 
phases). If phase II_L BP - phase II_E BP is ≤ 0,5 mmHg (1st step) and, if phase IV BP - phase I BP 
is ≤-7 mmHg (2nd step), a pathological nocturnal BP profile can be predicted with 87,5% 
sensitivity and 85,7% specificity. 
 
All figures and tables are reproduced from Fanciulli et al. (2014), Journal of Neurology; 261 (7): 1291-9 with 
permission from Springer Verlag GmbH. 
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4.5. Discussion 
The strong association between OH, the lack of peripheral vasoconstriction during phase 
II_L and phase IV of Valsalva maneuver and pathological nocturnal BP profiles observed in 
the present study, suggests that cardiac and vascular noradrenergic denervation may play 
a key role in the development of circadian BP rhythm disruptions in PD and MSA. Notably, 
the presence or lack of BP overshoots in the phase II_L and phase IV of the Valsalva 
maneuver has good within-subject reliability (Lawrence et al., 1992) and can be detected 
by naked-eye and in real-time during the execution of the Valsalva maneuver in standard 
tilt-table evaluations. Our results, therefore, suggest that, where this facility is available, 
tilt-table guided ABPM may increase the detection of pathological nocturnal BP profiles 
relevant for cerebrovascular and cognitive outcomes in parkinsonian disorders (Fanciulli 
et al., 2013). 
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5.1. Introduction 
As mentioned in the introduction, supine hypertension (SH) is an attending feature of 
cardiovascular autonomic failure in PD and MSA (Plaschke et al., 1998, Fanciulli et al., 
2014). It is usually asymptomatic or only manifest with vague complaints, but recent 
evidence suggests that the occurrence of OH and SH may play a negative prognostic role 
on survival, cardio- and cerebrovascular outcome as well on cognition in PD and MSA (Lim 
et al., 2009, Kim et al., 2012, Fanciulli et al., 2013, Oh et al., 2013, Pilleri et al., 2013, Jones 
et al., 2014). SH has been reported in approximately 50% of MSA patients with overt OH 
(Shannon et al., 1997, Biaggioni and Robertson, 2002), while no former study is available 
on the prevalence of SH in PD. Notably, no homogeneous cut-off values were used for the 
diagnosis of SH in the abovementioned papers. In the absence of consensus criteria, SH 
has been differently defined as systolic blood pressure (BP) ≥ 160 mmHg (Schutzman et 
al., 1994), ≥ 90 mmHg diastolic (Shannon et al., 1997) or ≥ 150 mmHg systolic/90 mmHg 
diastolic (Jordan et al., 1999). More recently, the American Heart Association fixed the 
cut-off for the diagnosis of hypertension to ≥140 mmHg systolic or ≥90 mmHg diastolic 
and defined three severity degrees, namely mild, moderate and severe hypertension, with 
different prognostic and therapeutic implications (Chobanian et al., 2003). 
In the present study, conceived by the cooperation between the Medical University of 
Innsbruck and the Sapienza University of Rome, we aimed at investigating the prevalence 
of SH according to the American Heart Association criteria in a large retrospective cohort 
of PD and MSA patients. Furthermore, we compared the prevalence and severity of SH 
between Parkinson’s disease with dementia (PDD) and gender-, age- and disease 
duration-matched non-demented PD patients and between MSA-P and gender-, age- and 
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disease duration-matched MSA-C patients. We finally assessed the clinical and tilt-test 
correlates of SH in PD and MSA. 
5.2. Materials and methods 
5.2.1. Study population 
Parkinsonian patients who underwent a diagnostic tilt-test examination in the time frame 
between January 2008 and August 2013 in Innsbruck or between January and November 
2011 in Rome were screened. 
Inclusion criteria were: i – diagnosis of probable PD according to the UK Brain Bank 
criteria (Hughes et al., 2001) OR; ii – diagnosis of probable PDD according to the 
International Parkinson Disease and Movement Disorder Society criteria (Emre et al., 
2007) OR; iii - diagnosis of probable MSA (parkinsonian or cerebellar variant) according to 
the 2nd Consensus conference on the diagnosis of MSA (Gilman et al., 2008); iv – 
extensive clinical documentation with at least two follow-up visits with confirmed 
neurological diagnosis. Exclusion criteria were: i –other major neurologic or psychiatric 
diseases; ii – missing or incomplete clinical documentation; iii – low quality of tilt-test 
examination.  
The study received approval by the local ethical committees and was performed 
according to the Declaration of Helsinki. Given the retrospective nature of the study, no 
written informed consent was due. Data were collected, archived and analysed 
anonymously following the current Austrian law for data protection. 
5.2.2. Clinical demographic data set 
For each enrolled patient, the following information was collected from clinical recordings 
contemporary to the tilt-test examination: i - age; ii – gender; iii – disease duration; iv – 
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Hoehn & Yahr stage; v – L-Dopa equivalent daily dosage calculated according to 
(Tomlinson et al., 2010); vi – cardiovascular comorbidities and risk factors (e.g. coronary 
arteries disease, atrial fibrillation, heart failure, history of hypertension, diabetes 
mellitus); vii – use of anti-hypotensive medications; viii – use of anti-hypertensive 
medications. 
5.2.3. Tilt-test data set 
In the above mentioned time frames, the Innsbruck and Rome cardiovascular autonomic 
function laboratories applied the same tilt-test protocols. Standard basic tilt-test protocol 
consisted of: 10 minutes supine, 10 minutes 60° head-up tilt, 5 minutes supine, 5 minutes 
active standing. Heart rate and BP were continuously monitored by means of non-
invasive beat-to-beat BP recording and impedance cardiography (Task Force® Monitor, 
CNSystems 2007). For the purposes of the present study, heart rate, systolic and diastolic 
BP values at 10th minute supine, 3rd and 10th minutes tilt, 5th minute supine, 3rd and 5th 
minutes standing were calculated by averaging 15 values of the continuous heart rate and 
BP recording at the above given time points.  
According to the American Heart Association criteria, SH was diagnosed in case of systolic 
BP ≥140 mmHg or diastolic ≥90 mmHg at the end of any supine phase. Mild hypertension 
was defined as systolic BP values of 140-159 mmHg or 90-99 mmHg diastolic, moderate 
hypertension as 160-179 mmHg systolic or 100-109 mmHg diastolic and severe 
hypertension  as ≥180 mmHg systolic or ≥110 mmHg diastolic (Chobanian et al., 2003). 
Following the 2011 consensus criteria, OH was defined as a systolic BP fall ≥ 20 mmHg or 
diastolic ≥10 mmHg within 3 minutes from tilting or standing in case of normal BP values 
in the supine position (Freeman et al., 2011). In case of SH, a systolic BP fall ≥ 30 mmHg 
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within 3 minutes from tilting or standing was required for the diagnosis of OH (Freeman 
et al., 2011). 
5.2.4. Statistics 
For descriptive purposes, qualitative variables were summarized by frequency and 
percentage. The Kolmogorow-Smirnow test was applied to proof the normal distribution 
of quantitative variables: latter were summarized by mean ± standard deviation if 
normally distributed, and by median (1st quartile; 3rd quartile) if not normally distributed. 
Qualitative variables were compared by means of the Pearson’s Χ2 test (or Fisher’s exact 
test, where appropriate). Depending on the distribution of data, quantitative variables 
were compared using the Mann-Whitney U (for non-normally distributed data) or the T-
test (for Gaussian distributed ones). 
Subgroup comparisons were run first. PDD were paired 1:2 with gender-, age- and disease 
duration-matched PD patients without dementia, while MSA-P and MSA-C patients were 
compared without preliminary matching. Benjamini-Hochberg correction was applied to 
multiple tests and a post-hoc power analysis was performed to determine the probability 
of type 2 error in both subgroups’ analysis. 
In a second step, a comparison of clinical demographic features between the overall PD 
(including PDD patients) and MSA (both MSA-P and MSA-C patients) populations was run 
and the prevalence and severity of SH in the diseases calculated. The prevalence of SH in 
PD and MSA was subsequently compared by including those clinical demographic 
parameters showing a significant difference between the PD and MSA cohorts in a logistic 
regression model.  
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In a third step, clinical and tilt-test characteristics of PD patients with versus those 
without SH were investigated in a univariate fashion. Subsequently, multivariate logistic 
regression analysis and repeated measurements ANOVA were performed to respectively 
assess the clinical and tilt-test correlates of SH in PD. The same procedure was applied to 
investigate the clinical and tilt-test correlates of SH in the setting of MSA. 
Statistical analysis was performed by means of SPSS®, version 20.0. P values < 0.05 were 
considered statistically significant. 
5.3. Results 
5.3.1. Study population 
An overview of the study flow chart is provided in Fig. 5.1. At the end of the screening 
procedure, data from 275 patients were available for the primary outcome analysis (10 
minutes in the supine position plus at least 3 minutes of 60° passive head-up tilt-test). In 
254 patients the tilt-test was prolonged up to 10 minutes. 191 patients additionally 
underwent an active standing test: in 11 patients the test was discontinued after 3 
minutes, while the remaining 180 patients completed it up to 5 minutes. 
Fig. 5.1 Supine hypertension study flow chart 
 
MSA-C: multiple system atrophy-cerebellar; MSA-P: multiple system atrophy-
parkinsonian; PD: Parkinson’s disease; PDD: Parkinson’s disease with dementia 
 
5.3.2. Parkinson’s disease versus Parkinson’s disease with dementia 
Thirty-three patients with PDD [22 males, 11 females; median age 74 years (72; 79, 1st; 3rd 
quartile); median disease duration 5 years (3; 10)] were matched with 66 non-demented 
PD patients [44 males, 22 females; median age 74 years (71; 79); median disease duration 
(3; 9)]. Full clinical-demographic and tilt-test characteristics are reported in Table 5.1. 
There was no difference in the L-Dopa equivalent daily dosage, prevalence of 
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cardiovascular comorbidities or use of anti-hypertensive and anti-hypotensive 
medications between the two groups. Patients with PDD were in a significantly more 
advanced Hoehn & Yahr stage with respect to PD ones [3(2; 3) versus 2.5 (2; 3), p=0.04].  
SH occurred in 27% of PDD patients and 44% of PD ones (p=0.108). Degree of SH was mild 
in 100% of PDD cases. In non-demented PD patients with SH, latter was mild in 76%, 
moderate in 21% and severe in 3% of cases, with no significant difference with respect to 
PDD (p=0.127). OH developed in 30% of PDD and 27% of PD patients at tilt-test 
examination (p=0.752). SH and OH co-occurred in respectively 9% and 14% of PDD and PD 
patients (p=0.383). No significant difference was observed in heart rate or BP behaviour 
upon tilting or standing between demented and non-demented patients. 
At post-hoc power analysis, the sample size had a 0.36 power to detect a significant 
difference in the prevalence of SH between demented and non-demented patients with 
PD, with a type I error of 0.05 (two-sided). 
A. Fanciulli - Cardiovascular autonomic failure in PD and MSA 
 
 
47 
Table 5.1 Clinical demographic and tilt-test characteristics in patients with Parkinson’s disease 
with dementia versus gender, age and disease-duration matched Parkinson’s disease patients 
without dementia. BP: blood pressure; HR: heart rate; OH: orthostatic hypotension; SH: supine 
hypertension. 
 
Parkinson’s disease 
with dementia Parkinson’s disease p 
Clinical demographic     
n 33 66 - 
Men, n (%) 22 (67) 44 (67) 1.000 
Age (yr), median (Q1; Q3) 74 (72; 79) 74 (71; 79) 0.908 
Disease duration (yr),  
median (Q1; Q3) 5 (3; 10) 4 (3; 9) 0.792 
Hoehn & Yahr stage,  
median (Q1; Q3) 3 (2; 3) 2.5 (2; 3) 0.04 
L-Dopa equivalent daily dose (mg),  
median (Q1; Q3) 400 (300; 1070) 463 (240; 1003) 0.988 
Cardiovascular comorbidities, n (%) 17 (51) 33 (50) 0.887 
Anti-hypertensive medications, n (%) 15 (46) 29 (44) 0.886 
Anti-hypotensive medications, n (%) 4 (12) 4 (6) 0.251 
    
Tilt-test     
OH, n (%) 10 (30) 18 (27) 0.752 
SH, n (%) 9 (27) 29 (44) 0.108 
SH severity_mild, n (%) 9 (100) 22 (76) 0.127 
SH severity_moderate, n (%) 0 (0) 6 (21)  
Sh severity_severe, n (%) 0 (0) 1 (3)  
SH+OH, n (%) 3 (9) 9 (14) 0.383 
Supine 10 min HR  
(n=33; 66), mean ± SD 70.6 ± 12.6 69.09 ± 11.5 0.568 
Supine 10 min systolic BP  
(n=33; 66), mean ± SD 119.6 ± 15.8 123.6 ± 15.8 0.242 
Supine 10 min diastolic BP  
(n=33; 66), mean ± SD 77.3 ± 11.3 81.4 ± 11.5 0.095 
3 min head-up tilt HR  
(n=33; 66), mean ± SD 79.9 ± 15.0 76.9 ± 13.2 0.305 
3 min head-up tilt systolic BP  
114.5 ± 21.8 121.0 ±  19.7 0.143 
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Parkinson’s disease 
with dementia Parkinson’s disease p 
(n=33; 66), mean ± SD 
3 min head-up tilt diastolic BP  
(n=33; 66), mean ± SD 80.3 ± 12.1 84.4 ±  11.2 0.096 
∆ HR 3 min head-up tilt  
(n=33; 66), mean ± SD 9.4 ± 8.8 7.8 ± 7.7 0.361 
∆ systolic BP 3 min head-up tilt  
(n=33; 66), mean ± SD -5.1  ±  15.0 -2.6  ± 17.1 0.480 
∆ diastolic BP 3 min head-up tilt  
(n=33; 66), mean ± SD 3.1  ±  10.0 3.1 ± 11.2 0.995 
Supine 5 min HR  
(n=24; 52), mean ± SD 73.2 ± 13.3 68.9 ± 13.8 0.214 
Supine 5 min systolic BP  
(n=24; 52), mean ± SD 117.8 ± 13.0 121.9 ± 14.2 0.240 
Supine 5 min diastolic BP  
(n=24; 52), mean ± SD 76.1 ± 9.6 82.1 ± 11.6 0.031 
Standing 3 min HR  
(n=24; 52), mean ± SD 83.5 ± 12.4 80. 0 ± 14.4 0.314 
Standing 3 min systolic BP  
(n=24; 52), mean ± SD 116.3 ± 24.4 127.4 ± 19.1 0.034 
Standing 3 min diastolic BP  
(n=24; 52), mean ± SD 80.7 ± 18.3 90.4 ± 13.8 0.012 
∆ HR 3 min standing   
(n=24; 52), mean ± SD 10.3  ±  7.3 11.1 ± 8.8 0.712 
∆ systolic BP 3 min standing  
(n=24; 52), mean ± SD -1.5  ±  24.3 5.5 ± 20.4 0.190 
∆ diastolic BP 3 min standing  
(n=24; 52), mean ± SD 4.5  ±  17.6 8.3 ± 15.7 0.349 
 
5.3.3. MSA-C versus MSA-P 
The MSA cohort consisted of 24 patients with MSA-C [15 males, 9 females; mean age 
62.8±8.2 years; median disease duration 3 years (2;4)] and 54 patients with MSA-P [35 
males, 19 females; mean age 65±9.3 years; median disease duration 3 (2; 4)]. Full clinical-
demographic and tilt-test characteristics are reported in 
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Table 5.2. MSA-C patients did not differ from MSA-P ones for any of the clinical 
demographic characteristic, except for L-Dopa equivalent daily dosage, which was higher 
in MSA-P patients [median dosage 600 (300; 1929) mg/day versus 0 (0; 300) mg/day, 
p<0.001).  
At tilt-test examination, SH occurred in 50% of MSA-C and 32% of MSA-P patients 
(p=0.118). In MSA-P the prevalence of severe SH was significantly higher (41% versus 8% 
in MSA-C, p=0.045). OH was present in 33% of MSA-C and 50% of MSA-P patients 
(p=0.172). Seventeen per cent of MSA-C patients and 26% of MSA-P ones developed both 
SH and OH at tilt-table examination (p=0.37). Heart rate or BP behaviour did not differ 
either upon head-up tilt or standing between MSA-C and MSA-P patients. 
At post-hoc power analysis, the sample size had a 0.34 power to detect a significant 
difference in the prevalence of SH between MSA-C versus MSA-P patients, with a type I 
error of 0.05 (two-sided). 
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Table 5.2 Clinical demographic and tilt-test characteristics in MSA-C versus MSA-P patients. BP: 
blood pressure; HR: heart rate; MSA-C: multiple system atrophy-cerebellar; MSA-P: multiple 
system atrophy-parkinsonism; OH: orthostatic hypotension; SH: supine hypertension 
 MSA-C MSA-P p 
Clinical demographic    
n 24 54 - 
Men, n (%) 15 (63) 35 (65) 0.520 
Age (yr), mean ± SD 62.8 ± 8.2 65 ± 9.3 0.302 
Disease duration (yr), median (Q1; Q3) 3 (2; 4) 3 (2; 5) 0.539 
Hoehn & Yahr stage, median (Q1; Q3) 4 (3; 5) 3 (2.5; 4) 0.252 
L-Dopa equivalent daily dose (mg),  
median (Q1; Q3) 0 (0; 300) 600 (300; 1929) <0.001 
Cardiovascular comorbidities, n (%) 11 (46) 25 (46) 0.583 
Anti-hypertensive medications, n (%) 10 (42) 15 (28) 0.225 
Anti-hypotensive medications, n (%) 4 (17) 5 (9) 0.279 
Tilt-test    
OH, n (%) 8 (33) 27 (50) 0.172 
SH, n (%) 12 (50) 17 (32) 0.118 
SH severity_mild, n (%) 9 (75) 7 (41) 0.045 
SH severity_moderate, n (%) 2 (17) 3 (18)  
Sh severity_severe, n (%) 1 (8) 7 (41)  
SH+OH, n (%) 4 (17) 14 (26) 0.37 
Supine 10 min HR  
(n=24; 54), mean ±SD 72.8 ± 11.1 73.2 ± 11.1 0.897 
Supine 10 min systolic BP  
(n=24; 54), mean ±SD 127.8 ± 12.9 124.2 ± 22.2 0.463 
Supine 10 min diastolic BP  
(n=24; 54), mean ±SD 85.2 ± 11.1 82.1 ± 18.8 0.458 
3 min head-up tilt HR  
(n=24; 54), mean ±SD 80.3 ± 10.3 79.7 ± 12.5 0.852 
3 min head-up tilt systolic BP  
(n=24; 54), mean ±SD 122.5 ± 22.6 113.2 ± 18.4 0.061 
3 min head-up tilt diastolic BP  
(n=24; 54), mean ±SD 88.0 ± 15.3 78.7 ± 15.8 0.018 
∆ HR 3 min head-up tilt  
7.4 ± 5.7 6.5 ± 6.6 0.565 
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 MSA-C MSA-P p 
(n=24; 54), mean ±SD 
∆ systolic BP 3 min head-up tilt  
(n=24; 54), mean ±SD -5.4 ± 18.5 -11.0 ± 18.8 0.224 
∆ diastolic BP 3 min head-up tilt  
(n=24; 54), mean ±SD 2.8 ± 12.9 -3.4 ± 14.5 0.074 
Supine 5 min HR  
(n=17; 26), mean ±SD 70.9 ± 11.4 74.2 ± 11.0 0.355 
Supine 5 min systolic BP  
(n=17; 26), mean ±SD 121.9 ± 23.5 124.7 ± 21.4 0.690 
Supine 5 min diastolic BP  
(n=17; 26), mean ±SD 84.4 ± 16.8 82.6 ± 16.3 0.724 
Standing 3 min HR  
(n=17; 26), mean ±SD 85.1 ± 10.5 81.8 ± 18.9 0.511 
Standing 3 min systolic BP  
(n=17; 26), mean ±SD 122.4 ± 19.7 116.8 ± 23.5 0.423 
Standing 3 min diastolic BP  
(n=17; 26), mean ±SD 87.5 ± 14.9 81.9 ± 17.3 0.278 
∆ HR 3 min standing   
(n=17; 26), mean ±SD 14.2 ± 7.2 7.6 ± 20.7 0.214 
∆ systolic BP 3 min standing  
(n=17; 26), mean ±SD .4 ± 25.0 -9.1 ± 18.9 0.162 
∆ diastolic BP 3 min standing  
(n=17; 26), mean ±SD 3.1 ± 15.9 -.7 ± 13.4 0.404 
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5.3.4. Prevalence of supine hypertension in PD and MSA 
Since no substantial difference was observed either in the clinical demographic or in the 
tilt-test characteristics among the PD (demented versus non-demented) and MSA (MSA-P 
versus MSA-C) subgroups, data were pooled and a cohort of 197 patients with PD and 78 
patients with MSA was available for the assessment of SH prevalence. Clinical 
demographic features of the overall PD and MSA cohorts are summarized in Table 5.3. 
Patients with PD (122 males, 75 females) had a median age of 71 years (65; 76, 1st; 3rd 
quartile), median disease duration of 5 years (3; 9) and median  2.5 (2; 3) Hoehn & Yahr 
stage. Median L-Dopa equivalent daily dosage was 510 mg/day (260; 1050). 
Cardiovascular comorbidities and risk factors were present in 40% of patients. Thirty-eight 
per cent of patients with PD took anti-hypertensive medications, 11% anti-hypotensive 
medications. 
MSA patients (50 males, 28 females) had a median age of 65 years (57; 72), median 
disease duration of 3 years (2; 4) and median 3 (3; 4) Hoehn & Yahr stage. Median L-Dopa 
equivalent daily dosage was 505 mg/day (200; 1103). Forty-six per cent of MSA patients 
had cardiovascular comorbidities in the medical history, 32% took anti-hypertensive 
drugs, 12% anti-hypotensives. 
As shown in Table 5.3, the PD and MSA cohort significantly differed for several clinical 
demographic characteristics, MSA patients being on average younger (p<0.001), with 
shorter disease duration (p<0.001), on lower daily dopaminergic dosage (p=0.004), but in 
a more advanced Hoehn & Yahr stage (p<0.001). 
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Table 5.3 Clinical demographic characteristics of the overall Parkinson’s disease (including 
Parkinson’s disease with dementia) and MSA (both parkinsonian and cerebellar variants) 
cohorts 
 PD MSA p 
n 197  78  - 
Men, n (%) 122 (62) 50 (64) 0.737 
Age (yr),  
median (Q1; Q3) 71 (65; 76) 65 (57; 72) <0.001 
Disease duration (yr),  
median (Q1; Q3) 5 (3; 9) 3 (2; 4) <0.001 
Hoehn & Yahr stage,  
median (Q1; Q3) 2.5 (2 ;3) 3 (3 ;4) <0.001 
L-Dopa equivalent daily dose (mg),  
median (Q1; Q3) 510 (260; 1050) 505 (200; 1103) 0.004 
Cardiovascular comorbidities, n (%) 78 (40) 36 (46) 0.32 
Anti-hypertensive medications, n (%) 75 (38) 25 (32) 0.35 
Anti-hypotensive medications, n (%) 11 (6) 9 (12) 0.087 
 
Prevalence of SH in the overall PD cohort was 34% (n=47). SH was mild in 71% of cases, 
moderate in 27% and severe in 2% (see Fig. 5.2). OH developed in 24% (n=66) of PD 
patients at tilt-test examination. In 10% (n=20) of PD patients, SH and OH co-occurred. 
In the MSA cohort, prevalence of SH was 37% (n=29). Degree of SH was mild in 55% of 
patients, moderate in 17% and severe in 28% (see Fig. 5.2). Forty-five per cent (n=35) of 
MSA patients had OH at tilt-test examination. Co-occurrence of SH and OH was observed 
in 23% (n=18) of patients. The prevalence of SH in MSA patients with OH was significantly 
higher than in MSA patients without OH (49% versus 26%, p=0.03). The prevalence of 
severe SH was also significantly higher in OH-positive MSA patients (44% versus 0% in OH-
negative patients, p=0.031). 
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After adjusting for age, disease-duration, Hoehn & Yahr stage and L-Dopa equivalent daily 
dosage, no difference was observed in the prevalence of SH between the PD and MSA 
cohort (OR=1.301, 95% confidence intervals: 0.6-2.8, p=0.5). 
Fig. 5.2 Prevalence and severity of supine hypertension in Parkinson’s disease and multiple 
system atrophy 
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5.3.5. Clinical and tilt-test correlates of supine hypertension in Parkinson’s disease 
At univariate analysis, a significant association between SH and the presence of 
cardiovascular comorbidities (p<0.001) as well as use of anti-hypertensive medications 
(p=0.03) was observed in PD. Lower HR increase (+7.4±7.8 versus +9.8±6.9, p=0.031), a 
more pronounced systolic (-6.1±18.4 versus +2±15.6, p=0.001) and diastolic (-0.6±12.7 
versus +7.3±11.6, p<0.001) BP fall after 3 minutes head-up tilt were observed in PD 
patients with SH with respect to those without (see Table 5.4).  
Full results of logistic regression analysis are reported in Table 5.5. The presence of 
cardiovascular comorbidities in the medical history significantly predicted SH at tilt-table 
examination in patients with PD (OR= 4.06, 95% confidence intervals: 1.6-10.0, p=0.002). 
ANOVA for repeated measurements confirmed a significant association between SH and 
progressive systolic (F=7.504, p=0.007) and diastolic (F=9.755, p=0.002) BP fall upon tilting 
in the PD cohort. The same association was observed for the standing test (F=7.157, 
p=0.008 for systolic BP and F=11.053, p=0.001 for diastolic BP fall). Heart rate behaviour 
did not differ between patients with or without SH either upon head-up tilt (F=0.735, 
p=0.392) or standing (F=1.283, p=0.259), (see Fig. 5.3). 
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Table 5.4 Clinical demographic and tilt-test characteristics in Parkinson’s disease patients with 
and without SH (univariate analysis). BP: blood pressure; HR: heart rate; OH: orthostatic 
hypotension; SH: supine hypertension. 
 SH - SH + p 
Clinical-demographic    
n 131  66  - 
Men, n (%) 78 (60) 44 (67) 0,331 
Age (yr), median (Q1; Q3) 70 (65; 75) 71 (66; 77) 0,139 
Disease duration (yr), median (Q1; Q3) 5 (3; 10) 5 (2; 9) 0,362 
Hohen & Yahr stage, median (Q1; Q3) 2,5 (2; 3) 2 (2; 3) 0,413 
L-Dopa equivalent daily dose (mg),  
median (Q1; Q3) 510 (300; 1060) 525 (100; 1055) 
0,313 
Cardiovascular comorbidities, n (%) 40 (31) 38 (58) <0,001 
Anti-hypertensive medications, n (%) 43 (33) 32 (49) 0,03 
Anti-hypotensive medications, n (%) 6 (5) 5 (8) 0,387 
    
Tilt test    
OH (%) 18 (27) 10 (30) 0,132 
Supine 10 min HR  
(n=131; 66), mean ± SD 
66,3 ± 11,0 73,5 ± 12,6 <0,001 
Supine 10 min systolic BP  
(n=131; 66), mean ± SD 
113,1 ± 12,5 136,9 ± 14,6 <0,001 
Supine 10 min diastolic BP  
(n=131; 66), mean ± SD 
73,2 ± 9,6 90,6 ± 8,9 <0,001 
∆ 3 min head-up tilt HR 
(n=131; 66), mean ± SD 9,8 ± 6,9 7,4 ± 7,8 0,031 
∆ 3 min head-up tilt systolic BP  
(n=131; 66), mean ± SD 2,0 ± 15,6 -6,1 ± 18,4 0,001 
∆ 3 min head-up tilt diastolic BP  
(n=131; 66), mean ± SD 7,3 ± 11,6 -0,6 ± 12,7 0,000 
∆ 10 min head-up tilt HR 
(n=123; 61), median (Q1; Q3) 
11 (5; 16) 8 (4; 10) 0,736 
∆ 10 min head-up tilt systolic BP 
(n=123; 61), mean ± SD 
-1,7 ± 14,6 -8,2 ± 19,6 0,023 
∆ 10 min head-up tilt diastolic BP 
(n=123; 61), mean ± SD 
2,2 ± 12,2 -4,2 ± 15,0 0,002 
Supine 5 min HR  66,9 ± 12,8 74,3 ± 13,7 0,001 
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 SH - SH + p 
(n=97; 51), mean ± SD 
Supine 5 min systolic BP  
(n=97; 51), mean ± SD 
113,7 ± 12,6 134,7 ± 15,1 <0,001 
Supine 5 min diastolic BP  
(n=97; 51), mean ± SD 
74,2 ± 8,5 89,8 ± 10,7 <0,001 
∆ 3 min standing HR 
(n=97; 51), mean ± SD 
9,8 ± 6,9 7,4 ± 7,8 0,031 
∆ 3 min standing systolic BP 
(n=97; 51), mean ± SD 
2,0 ± 15,6 -6,1 ± 18,4 0,001 
∆ 3 min standing diastolic BP 
(n=97; 51), mean ± SD 
7,3 ± 11,6 -0,6 ± 12,7 <0,001 
∆ 5 min standing HR  
(n=91; 50), median (Q1; Q3) 
13 (8; 18) 13 (5; 20) 0,218 
∆ 5 min standing systolic BP  
(n=91; 50), mean ± SD 
6,3 ± 17,4 -2,1 ± 19,2 0,009 
∆ 5 min standing diastolic BP 
(n=91; 50), mean ± SD 
8,7 ± 13,2 -0,1 ± 16,5 0,001 
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Table 5.5 Logistic regression analysis of clinical-demographic correlates of SH in Parkinson’s 
disease and MSA. OH: orthostatic hypotension; OR: odds ratio 
 p OR 95% confidence interval 
Parkinson’s disease    
Sex 0.45 1.29 0.7-2.5 
Age 0.81 1.00 1.0-1.0 
Disease duration 0.16 1.05 1.0-1.1 
Hoehn & Yahr stage 0.25 0.75 0.5-1.2 
L-Dopa equivalent dose 0.37 0.95 0.9-1.1 
Cardiovascular comorbidities 0.002 4.06 1.6-10.0 
Antihypertensive medications 0.47 0.72 0.3-1.8 
Antihypotensive medications 0.55 1.54 0.4-6.4 
OH 0.17 1.72 0.8-3.7 
    
MSA    
Sex 0.47 1.84 0.4-9.6 
Age 0.62 1.02 0.9-1.1 
Disease duration 0.62 1.10 0.8-1.6 
Hoehn & Yahr stage 0.24 1.78 0.7-4.7 
L-Dopa equivalent dose 0.01 0.54 0.3-0.9 
Cardiovascular comorbidities 0.30 0.39 0.1-2.3 
Antihypertensive medications 0.04 7.67 1.1-53.1 
Antihypotensive medications 0.93 0.89 0.1-12.0 
OH 0.002 15.26 2.8-83.7 
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Fig. 5.3 ANOVA for heart rate, systolic and diastolic BP changes upon head-up tilt and standing 
in Parkinson’s disease patients with (SH+) and without SH (SH-). BP: blood pressure; SH: supine 
hypertension; bpm: beats per minute 
 
5.3.6. Clinical and tilt-test correlates of supine hypertension in MSA 
In patients with MSA, univariate analysis showed a significant association between SH, 
lower L-Dopa equivalent daily dosage (P=0.003) and presence of OH at tilt-table 
examination (p=0.02). In MSA patients with SH, mean systolic BP change after 3 minutes 
of head-up tilt was -15.0±23.6 versus -5.9±14.4 in MSA patients without SH (p=0.065). 
Mean diastolic BP change after 3 minutes of head-up tilt was -4.1±18.1 in MSA patients 
with SH and 0.0±11.2 in those without SH (p=0.275), (see Table 5.6). 
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The logistic-regression model confirmed a significant association between SH, lower L-
Dopa equivalent daily dosage (0.54 OR, 95% confidence intervals: 0.3-0.9, p=0.01) and OH 
(15.26 OR, 95% confidence intervals: 2.8-83.7, p=0.002) in MSA patients. Additionally, a 
significant association between SH and use of anti-hypertensive medications was 
observed (7.67 OR, 95% confidence intervals: 1.1-53.1, p=0.04), (see Table 5.5).  
At ANOVA no difference in heart rate, systolic or diastolic BP behaviour was observed 
between MSA patients with and without SH, either upon head-up tilt (F=0.286, p=0.595 
for HR; F=2.434, p=0.124 for systolic BP; F=2.123, p=0.150 for diastolic BP) or standing 
(F=1.942, p=0.173 for HR; F=1.451, p=0.237 for systolic BP; F=1.536, p=0.224 for diastolic 
BP), (see Fig. 5.4). 
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Table 5.6 Clinical demographic and tilt-test characteristics in MSA with and without SH 
(univariate analysis). BP: blood pressure; HR: heart rate; OH: orthostatic hypotension; SH: 
supine hypertension 
 SH- SH+ p 
Clinical demographic    
n 49  29  - 
Men, n (%) 32 (65) 18 (62) 0.773 
MSA-P: MSA-C, n 37: 12 17:12 0.118 
Age (yr), mean ± SD 64.9 ± 9.4 63.5 ± 8.3 0.506 
Disease duration (yr), median (Q1; Q3) 3 (2; 6) 2 (2; 5) 0.363 
Hohen & Yahr stage, median (Q1; Q3) 3 (2.5; 4) 4 (3; 5) 0.329 
L-Dopa equivalent daily dose (mg),  
median (Q1; Q3) 550 (0; 1118) 0 (0; 400) 
0.003 
Cardiovascular comorbidities, n (%) 24 (49) 12 (41) 0.515 
Anti-hypertensive medications, n (%) 15 (31) 10 (35) 0.723 
Anti-hypotensive medications, n (%) 3 (6) 6 (21) 0.059 
OH (%) 17 (35) 18 (62) 0.02 
    
Tilt test    
Supine 10 min HR  
(n=49; 29), mean ± SD 72.2 ± 10.9 74.6 ± 11.2 0.354 
Supine 10 min systolic BP  
(n=49; 29), mean ± SD 114.8 ± 12.1 143.2 ± 17.4 <0.001 
Supine 10 min diastolic BP  
(n=49; 29), mean ± SD 75.0 ± 10.6 96.7 ± 16.7 <0.001 
∆ 3 min head-up tilt HR 
 (n=49; 29), mean ± SD 6.9 ± 6.7 6.6 ± 5.7 0.853 
∆ 3 min head-up tilt systolic BP 
(n=49; 29), mean ± SD -5.9 ± 14.4 -15.0 ± 23.6 0.065 
∆ 3 min head-up tilt diastolic BP  
(n=49; 29), mean ± SD 0.0 ± 11.2 -4.1 ± 18.1 0.275 
∆ 10 min head-up tilt HR  
(n=45; 25), median (Q1; Q3) 8.0 ± 6.4 8.6 ± 7.6 0.763 
∆ 10 min head-up tilt systolic BP  
(n=45; 25), mean ± SD -7.6 ± 21.7 -15.6 ± 18.6 0.122 
∆ 10 min head-up tilt diastolic BP 
(n=45; 25), mean ± SD -1.6 ± 12.7 -6.6 ± 15.3 0.145 
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 SH- SH+ p 
Supine 5 min HR  
(n=25; 18), mean ± SD 73.0 ± 9.9 72.7 ± 12.9 0.931 
Supine 5 min systolic BP  
(n=25; 18), mean ± SD 112.6 ± 11.2 139.0 ± 24.3 <0.001 
Supine 5 min diastolic BP  
(n=25; 18), mean ± SD 76.0 ± 9.6 93.5 ± 18.5 <0.001 
∆ 3 min standing  HR  
(n=25; 18), mean ± SD 14 (8; 21) 9 (4; 17) 0.082 
∆ 3 min standing systolic BP 
(n=25; 18), mean ± SD -1.1 ± 17.7 -11.3 ± 25.7 0.131 
∆ 3 min standing diastolic BP 
(n=25; 18), mean ± SD 2.8 ± 12.1 -2.1 ± 17.0 0.279 
∆ 5 min standing HR 
(n=23; 16), median (Q1; Q3) 13.5 ± 7.2 10.3 ± 9.5 0.238 
∆ 5 min standing systolic BP 
(n=23; 16), mean ± SD -1.3 ± 16.2 -8.3 ± 26.7 0.312 
∆ 5 min standing diastolic BP  
(n=23; 16), mean ± SD 0.9 ± 11.8 -3.8 ± 17.3 0.321 
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Fig. 5.4 ANOVA for heart rate, systolic and diastolic BP changes upon head-up tilt and standing 
in MSA patients with (SH+) and without SH (SH-). BP: blood pressure; SH: supine hypertension; 
bpm: beats per minute 
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5.4. Discussion 
To the best of our knowledge, this is the first study to investigate the prevalence of SH in 
PD and MSA according to the current consensus criteria for the diagnosis of hypertension 
(Chobanian et al., 2003).  
In the present retrospective cohort, the prevalence of SH in PD was 34%, in 71% of cases 
of mild degree. In MSA patients the prevalence of SH was 37%, of severe degree in 28% of 
cases. After adjusting for age, disease-duration, Hoehn & Yahr stage and L-Dopa 
equivalent daily dosage, the prevalence of SH did not differ between PD and MSA 
patients.  
Due to different criteria for the diagnosis of hypertension and BP measurement 
methodologies, only partial comparisons can be made with previously published data in 
the general population. In the Malmö study, which was run on 33.346 Swedish individuals 
with a mean age of 45.6 ± 7.4 years, hypertension was defined either as systolic BP ≥ 140 
mmHg, diastolic BP ≥ 90 mmHg at supine oscillometric BP measurement or use of anti-
hypertensive medications and occurred in 40% of subjects (Fedorowski et al., 2010). In 
the ARIC study, run on 12.433 black and white US natives, mean age in the 6th decade, 
hypertension at supine oscillometric BP measurement was reported in 30% of subjects 
without concomitant OH and 60% of patients with OH (Rose et al., 2000). Although 
oscillometric versus continuous BP measurement may not be directly comparable, and 
although the definition of hypertension differed among the studies, rough comparison 
would conclude that parkinsonian patients do have a comparable or slightly lower 
prevalence of SH with respect to the general population. It is however unclear whether 
the prevalence of moderate and severe SH, especially in MSA patients, differs from the 
general population.  
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In contrast with previous findings from Kim et al. (Kim et al., 2012), we did not observe 
any difference in the prevalence or severity of SH between PDD versus gender, age and 
disease duration matched PD patients without dementia. Severity of orthostatic BP fall, 
prevalence of OH or of combined OH and SH also did not differ between demented and 
non-demented PD patients. OH has been formerly associated with impaired attention, 
visuospatial and verbal memory in PD (Allcock et al., 2006, Peralta et al., 2007, Hohler et 
al., 2012, Pilleri et al., 2013). Hypertension has been also reported to exert an 
independent negative influence on executive function and delayed verbal memory in the 
setting of PD (Jones et al., 2014). Neurocirculatory abnormalities like OH and SH may be 
therefore associated with frontal executive dysfunction rather than overt dementia in PD. 
However, the results of the present study cannot exclude that non-demented PD patients 
suffering from OH, SH or both might be at higher risk of developing cognitive impairment 
in the future. An eventual causative relationship should be addressed in prospectively 
designed studies.  
In the present cohort, the prevalence of SH was 50% in MSA-C patients and 32% in MSA-P 
ones. OH occurred in 33% of MSA-C patients and 50% of MSA-P ones. Neither of these 
differences achieved statistical significance. Degree of orthostatic BP fall also did not 
differ between MSA-C and MSA-P patients. We were not therefore able to replicate 
previous findings reporting OH to be more frequent and  more severe in MSA-C with 
respect to MSA-P patients (Wenning et al., 2012). However, in the present study, MSA-P 
patients were on a significantly higher L-Dopa equivalent daily dosage with respect to 
MSA-C ones. Due to its renowned hypotensive effect, L-Dopa assumption might have on 
one hand lowered supine BP values, and on the other exacerbated orthostatic BP falls in 
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MSA-P patients, thus underestimating the prevalence of SH and overestimating that of 
OH in MSA-P. 
The pathophysiology of SH in PD and MSA is not fully clear at present. It was previously 
proposed that SH develops as side effect of vasoactive agents used for the treatment of 
OH: this hypothesis has been discarded by the observation that SH develops also in a 
substantial proportion of patients who do not take anti-hypotensive medications.  SH also 
likely represents a different nosological entity than essential hypertension, since 
parkinsonian patients with SH may have completely normal BP levels if measuring BP in 
the seated position.  
In PD we found SH to be associated with history of cardiovascular comorbidities and more 
severe orthostatic systolic and diastolic BP falls. Orthostatic BP falls reflect a combination 
of cardiovascular noradrenergic degeneration and baroreflex failure in Parkinson’s 
disease (Goldstein et al., 2003). Although speculative, it is therefore conceivable that in 
PD patients with pre-existing essential hypertension or predisposed to it, minor degrees 
of cardiovascular autonomic failure unmask or worsen hypertension when lying due to 
impaired baroreflex buffering. 
In MSA we found a strong association between SH and OH. This is in agreement with 
previous findings, reporting  residual sympathetic stimulation to cause even severe supine 
hypertension  in MSA due to autonomic failure-dependant hypersensitivity of 
noradrenergic receptors and lack of central autonomic modulation (Shannon et al., 1997). 
SH further showed an inverse relationship with L-Dopa equivalent daily dosage, as well as 
an association with use of anti-hypertensive medications in MSA. The inverse relationship 
between SH and L-Dopa daily intake may be explained in different ways: it may reflect 
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cases with more severe cardiovascular autonomic failure, who do tolerate only low L-
Dopa dosages; it may indicate more advanced cases in which a reduction of L-Dopa 
dosage followed lack of motor responsiveness or, yet, it may reflect L-Dopa 
vasodepressive properties, which are known to be augmented in patients with 
cardiovascular autonomic failure. The association between SH and use of anti-
hypertensive drugs in MSA probably reflects suboptimal therapeutic approaches, since 
normotensive BP values can be only achieved at the expenses of worsening a frequently 
co-existing OH.  
Our study has some limitations. First, due to its retrospective nature, we couldn’t collect 
systematic information on additional risk factors for hypertension like positive familial 
history, renal failure, serum lipids or smoking habit, although this latter is fairly 
uncommon among parkinsonian patients (Vanacore et al., 2000, Allam et al., 2004). 
Second, the present study cohort consisted of patients who had undergone a tilt-test 
examination for diagnostic purposes. This might have introduced a selection bias towards 
more severe cases, with symptomatic OH or suspected of atypical Parkinsonism. 
Notwithstanding, OH prevalence was 24% in the present PD population, which is in 
agreement with a recent meta-analysis, reporting the estimated pooled prevalence of OH 
to be 30% in PD (Velseboer et al., 2011). The prevalence of OH in the present MSA 
population (45%) was also consistent, if not lower, with previously reported data on large 
MSA cohorts (Gilman et al., 2005, Kollensperger et al., 2010). Third, we were not able to 
systematically document use of anti-hypotensive devices, like compression stockings or 
abdominal binders. However, according to the standard operating procedures of our 
cardiovascular autonomic function laboratories, patients who do wear such devices are 
invited to take them off during tilt test examinations. Eventual use of anti-hypotensive 
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devices should have therefore exerted only a minor influence on cardiovascular 
autonomic testing. Fourth, post-hoc analysis showed that both subgroups comparisons 
were underpowered to detect a significant difference in the prevalence of SH between PD 
patients with and without dementia or between MSA-C and MSA-P patients. Replication 
in larger cohorts is therefore needed to draw definitive conclusions as to these points. 
Concluding, more than one third of patients with Parkinson’s disease and MSA might 
suffer from SH in the context of cardiovascular autonomic failure. Due to its therapeutic 
and possibly prognostic implications, we suggest BP measurements in the supine and 
upright position to screen for SH and OH in the initial and follow-up diagnostic work-up of 
parkinsonian patients suspected of suffering from cardiovascular autonomic failure. 
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6.1. Introduction 
OH affects up to 52% of patients with PD (Bonuccelli et al., 2003, Allcock et al., 2006, 
Barone et al., 2009, Velseboer et al., 2011) and may be accompanied by paradox supine 
hypertension in one third of cases. Treatment is mandatory in case of symptomatic OH in 
order to improve quality of life and prevent potentially life-threatening conditions like 
syncope and injurious falls. Pharmacological treatment relies either on vasopressor 
agents (e.g. direct/indirect  1-adrenoreceptor agonists) or on drugs expanding 
intravascular volume (e.g. fludrocortisone, desmopressin) (Freeman, 2008), but 
exacerbation of supine hypertension is a common side effect. Non-pharmacological 
approaches are equally relevant for the clinical management of OH, either alone or in 
combination with drugs in more severe cases. The use of an elastic abdominal binder 
already proved effective in pediatric and adult patients with OH due to diabetes mellitus, 
pure autonomic failure, multiple system atrophy or of unknown etiology (Denq et al., 
1997, Tanaka et al., 1997, Smit et al., 2004, Podoleanu et al., 2006).  
Here we report the results of a single-centre, single-blinded, randomized, placebo-
controlled, cross-over trial to evaluate the effects of an elastic abdominal binder in 
reducing orthostatic BP fall upon tilting in a population of PD patients with OH. A 4-weeks 
open-label trial followed to evaluate the effect of elastic abdominal binders on OH-
related symptoms in daily living. 
6.2. Patients and methods 
6.2.1. Study population 
Fifteen consecutive patients with probable PD according to the UK Brain Bank criteria 
(Hughes et al., 2001) aged 40 to 90, with full legal competence and OH (Freeman et al., 
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2011) were recruited from the Movement Disorder Unit of the Innsbruck Medical 
University between May 2013 and March 2014. Exclusion criteria were: other major 
neurologic, psychiatric or cardiac diseases, untreated diabetes mellitus with clinical 
features of peripheral neuropathy, varicose veins, known or suspected pregnancy, breast 
feeding, Hoehn & Yahr stage ≥ 4 or changes of the pharmacological therapy in the 6 
weeks preceding enrolment. 
The study received approval by the local ethical committee, was performed according to 
the declaration of Helsinki and was registered in ClinicalTrials.gov (Identifier: 
NCT01971008, ABOHP study). After giving written informed consent, each patient 
underwent thorough neurological and cardiological examinations. The following scales 
were administered at baseline: Unified PD Rating Scale (UPDRS), non-motor symptoms 
scale (NMSS), autonomic scale for outcomes in PD (SCOPA-AUT) and orthostatic 
hypotension questionnaire (OHQ). 
6.2.2. Study design  
An outline of the study flow chart is provided in Fig. 6.1. A single-blinded, randomized, 
placebo-controlled, cross-over design was adopted. For allocation of participants, a 
randomization sequence was generated on a computer-basis and kept in an agreed place, 
to which the recruiting investigator had no access. According to this sequence, patients 
were randomly assigned to first receive either an elastic abdominal binder (Abdo-Syncro 
3-stripes abdominal binder, Syncro Med GmbH) or a placebo binder (Clima Care body 
warmer, Bort Medical GmbH). 
On study day-1, all patients underwent a 1st baseline tilt-test examination. Afterwards 
they were asked to wear the assigned binder. 2 hours later, the 1st study tilt-test was 
A. Fanciulli - Cardiovascular autonomic failure in PD and MSA 
 
 
72 
performed. The binder was subsequently taken off. On study day-2 a wash-out was 
operated. On study day-3, the patients underwent a 2nd baseline tilt-test, wore the other 
type of binder and 2 hours later had the 2nd study tilt-test. Participants were blinded to 
the type of binder during the cross-over phase. The investigator performing the tilt-test 
examination (AF) was not, since he had to check whether the binder exerted the 
appropriate pressure (20±2 mmHg for the elastic abdominal binder, 3±2 mmHg for the 
placebo binder) by placing a slightly inflated sphygmomanometer between the binder and 
the abdominal wall of the patient. 
All the tilt-tests were performed between 9 a.m. and 12 p.m. under continuous non-
invasive HR and BP monitoring (Task Force® Monitor, CNSystems 2007). On examination 
days, patients were invited not to drink any coffee, tea or taurine-containing beverages, 
but to take their medications regularly and to have their meals at least two hours before 
the scheduled tilt-test. 
The following protocol was applied: 10 minutes supine, 10 minutes 60° head-up tilt, 5 
minutes supine, 5 minutes active standing. Systolic, diastolic and mean BP values at 10th 
minute supine, 3rd and 10th minutes tilt, 5th minute supine, 3rd and 5th minutes standing 
were calculated in an automatized way by averaging 15 values of the continuous BP 
recording at the above given time points. If continuous BP recording failed, oscillometric 
BP records at the same time points were used for data analysis.  
Once the cross-over phase was over, each patient was invited to wear the elastic 
abdominal binder every day during daytime. Four weeks later a phone interview took 
place, in which patient’s compliance was assessed and the OHQ repeated. 
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Fig. 6.1 ABOHP study design 
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6.2.3. Study outcomes 
Effect of the elastic abdominal binder versus placebo on mean BP change after 3 minutes 
of head-up tilt was defined as primary outcome. Secondary outcomes were:  
 effect of the elastic abdominal binder versus placebo on systolic BP changes after 
3 minutes of head-up tilt; 
 effect of the elastic abdominal binder versus placebo on diastolic BP changes after 
3 minutes of head-up tilt; 
  effect of the elastic abdominal binder versus placebo on mean BP change after 3 
minutes of standing test; 
 effect of the elastic abdominal binder versus placebo on mean supine BP  
 changes of the OHQ score after 4-weeks open-label regular use of the elastic 
abdominal binder with respect to baseline. 
6.2.4. Statistics 
Sample size of the present study was calculated according to previously published data on 
elastic abdominal binders (Smit et al., 2004, Podoleanu et al., 2006): 14 patients had to 
enter the 2-arms cross-over study with a 80% probability to detect a 10 mmHg treatment 
difference (SD 10 mmHg) at one-sided 0.05 significance level. The number of participants 
was rounded to 15 in order to counteract eventual drop-outs.  
BP changes (hereinafter indicated as Δ) at 3rd minute of head-up tilt and at 3rd minute of 
standing test were calculated as follow: 
 Δ 3rd minute tilt mean/systolic/diastolic BP = (3rd minute tilt 
mean/systolic/diastolic BP) - (10th minute supine mean/systolic/diastolic BP) 
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 Δ 3rd minute standing mean BP = (3rd minute standing mean BP) - (5th minute 
supine mean BP) 
Effects of the elastic abdominal binder or placebo binder on supine BP or orthostatic BP 
changes were calculated with respect to the baseline examination of the same day in the 
following way: 
 Δ 10th minute supine mean BP= (10th minute supine mean BP with abdominal 
binder/placebo)- (10th minute supine mean BP at respective baseline tilt-test) 
 Δ 3rd minute tilt mean/systolic/diastolic BP = (Δ 3rd minute tilt 
mean/systolic/diastolic BP with abdominal binder/placebo) – (Δ 3rd minute tilt 
mean/systolic/diastolic BP at respective baseline tilt-test) 
 Δ 3rd minute standing mean BP= (Δ 3rd minute standing mean BP with abdominal 
binder/placebo) - (Δ 3rd minute standing mean BP at respective baseline tilt-test) 
Normal distribution of data was proofed with the Shapiro-Wilk test. Paired T-test was 
applied to evaluate vasopressor differences between the abdominal binder and the 
placebo binder at the above given time points. OHQ score changes after 4-weeks open-
label follow-up were compared to baseline visit by means of the Wilcoxon signed-rank 
test. 
Statistical analysis was performed using SPSS®, version 20.0. P values < 0.05 were 
considered statistically significant. 
6.3. Results 
Three patients dropped out from the study during the cross-over phase: two patients 
from the abdominal binder-placebo group (one because OH was not confirmed at 1st 
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baseline tilt-test on study day-1, one because receiving intravenous NSAIDs on study day-
3 for low back pain) and one patient from the placebo-abdominal binder group because 
of syncope before 3 minutes during the 1st baseline tilt-test on study day-1 (missing 
baseline data for the primary outcome). Data from 12 patients (4 from the abdominal 
binder-placebo group, 8 from the placebo-abdominal binder group) were therefore 
available for the primary outcome analysis. Clinical and demographic characteristics of 
the study population are reported in Table 6.1. 
The abdominal binder increased 3rd minute tilt mean BP by +7.7 mmHg [(+3.5; +11.9), 
95% c.i] with respect to baseline examination. Compared to the placebo binder +10 
mmHg [(+3.5; +16.5), p=0.006] mean BP increase at 3rd minute tilt was observed. 
3rd minute head-up tilt systolic BP increased by +15.5 mmHg [(+5.9; +25.1), p=0.005] with 
the abdominal binder with respect to placebo and diastolic BP by +7.3 mmHg [(+1; +13.5), 
p=0.027]. The abdominal binder had no effect on supine mean BP values compared to 
placebo [+4.8 mmHg (-4.9; +14.5), p=0.3]. 
Two patients were further excluded from the analysis of Δ 3rd minute standing mean BP 
because of syncope within the 1st minute of baseline standing test. A trend towards 
increase of mean BP at 3rd minute standing was observed with the abdominal binder 
versus placebo [+13 mmHg (-0.3; +26.2), p=0.054].  
During the open-label phase, the patients wore the abdominal binder an average of 5.6 
(±0.6) days/week, 50-75% of daytime. Mean composite OHQ score at baseline was 5.2 
(4.2-6.2, 95% c.i.), mean OH Symptom Assessment (OHSA) subscore was 4.9 (3.8-5.9, 95% 
c.i.) and mean OH Daily Activity Scale (OHDAS) was 5.6 (4.3-6.8, 95% c.i.). At 4-weeks 
follow-up a -2.5 points [(-3.4; -1.5) 95% c.i., p=0.003] reduction of the composite OHQ 
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score was observed. The OHSA subscore decreased by -2.1 points [(-3.0; -1.1), p=0.003] 
and the OHDAS by -3.4 [(-5.0; -1.7), p=0.007]. 
No side effect was observed during the cross-over phase. One patient with history of 
gastro-oesophageal reflux reported mild exacerbation of symptoms during the open-label 
follow-up. 
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Table 6.1 ABOHP study. Demographic and clinical characteristics of the study cohort. If not 
otherwise specified, values are reported as median (1st quartile; 3rd quartile). UPDRS: Unified 
Parkinson’s Disease Rating Scale; NMSS: Non Motor Symptom Scale; SCOPA-AUT: Autonomic 
Scale for Outcomes in Parkinson’s disease 
*L-Dopa equivalent daily dosage calculated according to (Tomlinson et al., 2010) 
**Compression stockings 
Characteristic Value 
n 12 
Gender (M:F) 8: 4 
Age (years) 69 (66; 75) 
Disease duration (years) 6 (3; 12) 
Hoehn & Yahr stage 2 (2; 2,5) 
L-dopa equivalent dose* (mg/day) 555 (228; 1690) 
Use of anti-hypertensives, n (%) 6 (50) 
Use of anti-hypotensives, n (%) 2 (24) 
Use of anti-hypotensive devices, n (%)** 2 (24) 
UPDRS total score 54 (41; 66) 
UPDRS - part I 12 (8; 18) 
UPDRS - part I_item 12 (cardiovascular) 2,5 (1; 3) 
UPDRS - part II 13 (9; 15) 
UPDRS - part III 29 (19; 36) 
NMSS total score 81 (50; 106) 
NMSS cardiovascular subscore 8 (4; 8) 
SCOPA-AUT total score 21 (14; 29) 
SCOPA-AUT cardiovascular subscore 4 (2; 6) 
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6.4. Discussion  
Our study confirms the previously reported (Tanaka et al., 1997, Smit et al., 2004, 
Podoleanu et al., 2006) efficacy of elastic abdominal binders in reducing OH and extends 
its validity to PD (level I evidence). The binder had no influence on supine mean BP levels 
(level I evidence) and a clinically relevant (Kaufmann et al., 2012) amelioration of OH 
symptoms was observed at open-label follow-up (level III evidence). The heterogeneity of 
the study population as to gender, age-range, disease-duration and severity suggests the 
results of the present study to be generalizable to both early and advanced disease stages 
of PD.  
The mechanism of action of an elastic abdominal binder is entirely mechanical: it prevents 
orthostatic BP fall by reducing splanchnic venous pooling upon standing (Smit et al., 
2004). Its use for the management of OH may thus result profitable under several points 
of view: since not inducing pharmacological interactions, it may be preferable in patients 
with complex therapeutic schedules; not increasing supine BP, it may be preferred in case 
of overt supine hypertension and, being less cumbersome to wear than compression 
stockings, it may achieve higher compliance in advanced stages. 
Some limits need to be addressed to our study. First, the investigator performing the tilt 
tests was not blinded, since such examinations need to be performed bare-chested for 
safety reasons. However, to minimize the risk of bias, outcome measures were collected 
in an automated way. Second, patients with varicose veins were excluded. Although 
previous studies reported no change of femoral vein diameter from a 40 mmHg pressure 
on the abdominal wall (Smit et al., 2004), we cannot exclude that abdominal binders 
worsen leg venous insufficiency in the long-term. Third, we cannot either exclude that the 
exacerbation of gastro-oesophageal reflux reported from one patient during follow-up 
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was not related to the abdominal binder. Finally, the effect of the elastic abdominal 
binder on daily OH-related symptomatic burden was investigated in an open-label fashion 
only. 
Concluding, our findings suggest that elastic abdominal binders may be a simple and 
complementary tool to alleviate OH in PD patients. Further randomized placebo-
controlled trials to replicate the effect of elastic abdominal binders on OH symptomatic 
burden in daily living are warranted. 
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7. Conclusions and outlook 
The studies here within presented showed that: 
1. There’s an association between cardiovascular autonomic failure and shorter 
survival as well as worse cardiovascular, cerebrovascular and cognitive outcome 
in PD and MSA. Association does not however imply causation. Prospectively 
designed studies are needed to assess whether cardiovascular autonomic failure 
actually exerts a negative prognostic role in -synucleinopathies and, if yes, which 
is the single contribution of OH and supine/nocturnal hypertension in this 
context. This information will turn essential to assess the long-term benefit-risk 
ratio of treating OH versus supine/nocturnal hypertension in single patients. 
2. According to the results of our proof-of-concept study, the naked-eye evaluation 
of BP behavior during phase II-L and phase IV of the Valsalva maneuver may 
represent a sensitive and specific screening test for nocturnal hypertension in PD 
and MSA during tilt-table examinations without additional costs. If replicated in 
larger cohorts, with concomitant 24h-ABPM and sleep monitoring, this two-step 
decision-support algorithm may represent a time-sparing approach to improve 
the detection of a modifiable cardiovascular risk factor by tilt-table guided 24h-
ABPM in parkinsonian patients.  
3. Against prior belief that parkinsonian patients have a lower risk of developing 
hypertension, we found that PD and MSA patients may suffer from supine 
hypertension to a similar extent as in the general population and that, especially 
in MSA, hypertension might be of severe degree in one third of cases. We did not 
find a higher prevalence of neurocirculatory abnormalities (either OH or supine 
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hypertension) in PD patients with dementia versus gender, age and disease 
duration matched PD patients without dementia. Since an association between 
cardiovascular autonomic failure and impairment of diverse executive functions 
has been already reported in the literature, this may imply that cardiovascular 
autonomic failure is associated with frontal executive dysfunction rather than 
with overt dementia in PD. Due to the cross-sectional nature of our observations, 
we cannot however exclude that PD patients without dementia but with 
cardiovascular autonomic failure might be at higher risk of developing dementia 
during the disease course. Prospectively designed studies are necessary to further 
clarify this issue. The results of our study also support the hypothesis that SH in 
MSA develops after hypersensitive adrenergic response to unrestrained tonic 
sympathetic stimulation, while in PD minor degrees of cardiovascular baroreflex 
failure likely unmask hypertension in the supine position in predisposed 
individuals. It is however unclear at present, whether additional factors 
contribute to the development of nocturnal hypertension. Further studies 
addressing the pathophysiology of supine and nocturnal hypertension and their 
relationship in in the setting of parkinsonian syndromes are needed to develop 
targeted pharmacological strategies. 
4. Elastic abdominal binders represent a simple non-pharmacological approach to 
attenuate orthostatic BP fall, without increasing supine BP levels in PD patients 
suffering from OH (level I evidence). We also provide level III evidence that 
regular use of elastic abdominal binders may reduce OH-related symptomatic 
burden in daily living. Replication in randomized, placebo-controlled clinical is 
needed to proof this observation. 
A. Fanciulli - Cardiovascular autonomic failure in PD and MSA 
 
 
83 
8. Related publications 
8.1. Papers 
1. Fanciulli A, Goebel G, Ndayisaba JP, Granata R, Dürr S, Strano S, Colosimo C, 
Poewe W, Pontieri FE, Wenning GK. Supine hypertension in Parkinson’s disease 
and Multiple System Atrophy. In preparation. 
2. Fanciulli A, Goebel G, Metzler B, Sprenger F, Poewe W, Wenning GK, Seppi K. 
Elastic abdominal binders attenuate orthostatic hypotension in Parkinson’s 
disease: a randomized controlled trial. In preparation  
3. Fanciulli A, Strano S, Ndayisaba JP, Goebel G, Gioffrè L, Rizzo M, Colosimo C, 
Caltagirone C, Poewe W, Wenning GK, Pontieri FE. Detecting nocturnal 
hypertension in Parkinson's disease and multiple system atrophy: proposal of a 
decision-support algorithm.  J Neurol, 2014; 261(7):1291-9.  
4. Fanciulli A, Strano S, Colosimo C, Caltagirone C, Spalletta G, Pontieri FE. The 
potential prognostic role of cardiovascular autonomic failure in α-
synucleinopathies.  Eur J Neurol, 2013; 20 (2): 231-235. 
5. Fanciulli A, Assogna F, Caltagirone C, Spalletta G, Pontieri FE. Rotigotine for non-
motor symptoms of wearing-off in Parkinson’s Disease with Dementia.  Aging Clin 
Exp Res, 2013; 25 (5): 601-603. 
6. Berardelli A, Wenning GK, Antonini A, Berg D, Bloem BR, Bonifati V, Brooks D, Burn 
D, Colosimo C, Fanciulli A, Ferreira J, Gasser T, Grandas F, Kanovsky F, Kostic V, 
Kulisewsky J, Oertel W, Poewe W, Reese JP, Relja M, Ruzicka E, Shapira A, Schrag 
A, Seppi K, Taba P, Vidalhet M. EFNS/MDS-ES Recommendations for the diagnosis 
of Parkinson’s Disease. Eur J Neurol, 2013; 20 (1): 16-34. 
7. Pellicano C, Benincasa D, Fanciulli A, Latino P, Giovannelli M, Pontieri FE. The 
impact of extended release dopamine agonists on prescribing patterns for therapy 
of early Parkinson’s disease: an observational study. Eur J Med Res, 2013; 18 (1): 
60. 
 
A. Fanciulli - Cardiovascular autonomic failure in PD and MSA 
 
 
84 
8.2. Book and book chapters 
1. Multiple System Atrophy, edited by Gregor K. Wenning & Alessandra Fanciulli. 
Springer Verlag, 2014. 
2. Fanciulli A, Wenning GK (book chapter) Chapter 1: Historical review. Multiple 
System Atrophy, edited by Gregor K. Wenning & Alessandra Fanciulli. Springer 
Verlag, 2014, pp. 1-9. 
3. Fanciulli A, Wenning GK (book chapter) Chapter 6: Clinical presentation. Multiple 
System Atrophy, edited by Gregor K. Wenning & Alessandra Fanciulli. Springer 
Verlag, 2014, pp. 97-119. 
4. Fanciulli A, Wenning GK (book chapter) Chapter 7: Clinical diagnostic criteria. 
Multiple System Atrophy, edited by Gregor K. Wenning & Alessandra Fanciulli. 
Springer Verlag, 2014, pp: 121-132. 
5. Fanciulli A, Wenning GK (book chapter) Chapter 8: Natural hystory. Multiple 
System Atrophy, edited by Gregor K. Wenning & Alessandra Fanciulli. Springer 
Verlag, 2014, pp. 133-142. 
6. Fanciulli A, Wenning GK (book chapter) Chapter 10: Treatment. Multiple System 
Atrophy, edited by Gregor K. Wenning & Alessandra Fanciulli. Springer Verlag, pp. 
169-194. 
7. Wenning GK, Fanciulli A. (book chapter) Dysautonomia in Movement Disorders. 
Movement Disorders in Neurologic & Systemic Disease, edited by W.Poewe and J. 
Jankovic. Cambridge University Press, 2014; (V) 24: 363-382. 
 
A. Fanciulli - Cardiovascular autonomic failure in PD and MSA 
 
 
85 
8.3. Non peer-reviewed publications 
1. Fanciulli A, Wenning GK. Screening nächtlicher Hypertonie bei M. Parkinson und 
MSA: ein Algorithmus (Screening of nocturnal hypertension in Parkinson’s disease 
and multiple system atrophy: an algorithm). Neurologisch, 2014; 2: 64. 
2. Fanciulli A, Wenning GK. Verzögerte orthostatische Hypotonie bei Morbus 
Parkinson (Delayed orthostatic hypotension in Parkinson’s disease). Neurologisch, 
2013; 4: 38-39. 
3. Fanciulli A, Wenning GK. Diagnose und Behandlung der nächtlichen und liegenden 
Hypertonie bei Parkinson-Syndromen (Diagnosis and therapy of nocturnal and 
supine hypertension in parkinsonian syndromes). Neurologisch, 2013; 2: 132-133. 
4. Fanciulli A, Pontieri FE, Wenning GK. Kardiovaskuläres Risiko und Mortalität bei 
Synukleinopathien (Cardiovascular risk and mortality in -synucleinopathies). 
Neurologisch, 2012; 4: 96-99. 
5. Fanciulli A, Krismer F, Wenning GK. Klinik, Diagnostik und Therapie autonomer 
Störungen bei Morbus Parkinson und anderen Parkinson Syndromen (Diagnosis 
and therapy of autonomic failure in Parkinson’s disease and other parkinsonian 
syndromes). P-Aktuell, 2012; 4: 1-20. 
 
A. Fanciulli - Cardiovascular autonomic failure in PD and MSA 
 
 
86 
9. Scientific awards 
1. 2013 LIMPE “Giovani e Ricerca” Research Award for the best presentation of the 
project “Supine Hypertension in Parkinson’s disease and multiple system atrophy”. 
2. 2013 Research Award of the Austrian Parkinson Society for the project “Detecting 
nocturnal hypertension in Parkinson's disease and multiple system atrophy: 
proposal of a decision-support algorithm” 
3. 2013 International Parkinson’s disease and Movement Disorders Society Travel 
Grant for the project “Cardiovascular autonomic failure in Parkinson’s disease with 
dementia” 
 
 
 
 
 
 
 
 
A. Fanciulli - Cardiovascular autonomic failure in PD and MSA 
 
 
87 
10. Acknowledgements 
First and foremost I’d like to thank my advisors Prof. Francesco E. Pontieri and Prof. 
Gregor K. Wenning for trusting and granting me highly valuable professional chances 
throughout the Doctoral years. I could perceive true generosity in your mentoring.  
I’m grateful to Prof. Werner Poewe for providing thoughtful advice and judging different 
cultural backgrounds as a resource to benefit of, to Prof Klaus Seppi for sharing his 
scientific enthusiasm and wide methodological knowledge and to Prof. Georg Göbel for 
his expert advice and open-mindedness. 
I wish to thank my colleagues of the Rome Movement Disorder Unit, Innsbruck 
Neurobiology Unit, Innsbruck Parkinson Study Group, Rome Cardiovascular Autonomic 
Function Lab and Rome Santa Lucia Foundation. Daily source of professional and personal 
growth. 
I also thank the Sapienza University of Rome and the Medical University of Innsbruck for 
providing financial support during the PhD fellowship. 
To my family and friends scattered around the world for their unconditioned warmth. 
To the G who was already there, to the one who changed the rules and to the one who 
came in medias res. Voi siete il sale della mia terra. 
            
                    Alessandra Fanciulli 
 
A. Fanciulli - Cardiovascular autonomic failure in PD and MSA 
 
 
88 
11. References 
Allam MF, Campbell MJ, Hofman A, Del Castillo AS, Fernandez-Crehuet Navajas R. 
Smoking and Parkinson's disease: systematic review of prospective studies. Mov Disord. 
2004;19(6):614-21. 
 
Allcock LM, Kenny RA, Mosimann UP, Tordoff S, Wesnes KA, Hildreth AJ, et al. Orthostatic 
hypotension in Parkinson's disease: association with cognitive decline? Int J Geriatr Psychiatry. 
2006;21(8):778-83. 
 
Asahina M, Vichayanrat E, Low DA, Iodice V, Mathias CJ. Autonomic dysfunction in 
parkinsonian disorders: assessment and pathophysiology. J Neurol Neurosurg Psychiatry. 2012. 
 
Auyeung M, Tsoi TH, Mok V, Cheung CM, Lee CN, Li R, et al. Ten year survival and 
outcomes in a prospective cohort of new onset Chinese Parkinson's disease patients. J Neurol 
Neurosurg Psychiatry. 2012;83(6):607-11. 
 
Barone P, Antonini A, Colosimo C, Marconi R, Morgante L, Avarello TP, et al. The PRIAMO 
study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in 
Parkinson's disease. Mov Disord. 2009;24(11):1641-9. 
 
Benarroch EE. The central autonomic network: functional organization, dysfunction, and 
perspective. Mayo Clin Proc. 1993;68(10):988-1001. 
 
Benarroch EE. Brainstem in multiple system atrophy: clinicopathological correlations. Cell 
Mol Neurobiol. 2003;23(4-5):519-26. 
 
Benarroch EE, Schmeichel AM, Sandroni P, Low PA, Parisi JE. Involvement of vagal 
autonomic nuclei in multiple system atrophy and Lewy body disease. Neurology. 2006;66(3):378-
83. 
 
Berganzo K, Diez-Arrola B, Tijero B, Somme J, Lezcano E, Llorens V, et al. Nocturnal 
hypertension and dysautonomia in patients with Parkinson's disease: are they related? J Neurol. 
2013;260(7):1752-6. 
 
Biaggioni I, Robertson RM. Hypertension in orthostatic hypotension and autonomic 
dysfunction. Cardiology clinics. 2002;20(2):291-301, vii. 
 
Bonuccelli U, Lucetti C, Del Dotto P, Ceravolo R, Gambaccini G, Bernardini S, et al. 
Orthostatic hypotension in de novo Parkinson disease. Arch Neurol. 2003;60(10):1400-4. 
 
Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain 
pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003;24(2):197-211. 
Bradbury S EC. Postural hypotension. A report of three cases. American Heart Journal. 1925;1:73-
86 
Brown RG, Lacomblez L, Landwehrmeyer BG, Bak T, Uttner I, Dubois B, et al. Cognitive 
impairment in patients with multiple system atrophy and progressive supranuclear palsy. Brain. 
2010;133(Pt 8):2382-93. 
A. Fanciulli - Cardiovascular autonomic failure in PD and MSA 
 
 
89 
Calandra-Buonaura G, Guaraldi P, Sambati L, Lopane G, Cecere A, Barletta G, et al. 
Multiple system atrophy with prolonged survival: is late onset of dysautonomia the clue? Neurol 
Sci. 2013;34(10):1875-8. 
 
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr., et al. Seventh 
report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of 
High Blood Pressure. Hypertension. 2003;42(6):1206-52. 
 
Chobanian AV, Volicer L, Tifft CP, Gavras H, Liang CS, Faxon D. Mineralocorticoid-induced 
hypertension in patients with orthostatic hypotension. N Engl J Med. 1979;301(2):68-73. 
 
Cilia R, Cereda E, Klersy C, Canesi M, Zecchinelli AL, Mariani CB, et al. Parkinson's disease 
beyond 20 years. J Neurol Neurosurg Psychiatry. 2014. 
 
Czajkowska J, Ozhog S, Smith E, Perlmuter LC. Cognition and hopelessness in association 
with subsyndromal orthostatic hypotension. The journals of gerontology Series A, Biological 
sciences and medical sciences. 2010;65(8):873-9. 
 
Davies B, Sudera D, Sagnella G, Marchesi-Saviotti E, Mathias C, Bannister R, et al. 
Increased numbers of alpha receptors in sympathetic denervation supersensitivity in man. J Clin 
Invest. 1982;69(4):779-84. 
 
de Leeuw FE, de Groot JC, Oudkerk M, Witteman JC, Hofman A, van Gijn J, et al. 
Hypertension and cerebral white matter lesions in a prospective cohort study. Brain. 2002;125(Pt 
4):765-72. 
 
Deguchi K, Takeuchi H, Sasaki I, Tsukaguchi M, Touge T, Nishioka M. Impaired novelty P3 
potentials in multiple system atrophy--correlation with orthostatic hypotension. J Neurol Sci. 
2001;190(1-2):61-7. 
 
Denq JC, Opfer-Gehrking TL, Giuliani M, Felten J, Convertino VA, Low PA. Efficacy of 
compression of different capacitance beds in the amelioration of orthostatic hypotension. Clin 
Auton Res. 1997;7(6):321-6. 
 
Eigenbrodt ML, Rose KM, Couper DJ, Arnett DK, Smith R, Jones D. Orthostatic hypotension 
as a risk factor for stroke: the atherosclerosis risk in communities (ARIC) study, 1987-1996. Stroke. 
2000;31(10):2307-13. 
 
Elmstahl S, Rosen I. Postural hypotension and EEG variables predict cognitive decline: 
results from a 5-year follow-up of healthy elderly women. Dementia and geriatric cognitive 
disorders. 1997;8(3):180-7. 
 
Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, et al. Clinical diagnostic 
criteria for dementia associated with Parkinson's disease. Mov Disord. 2007;22(12):1689-707; quiz 
837. 
 
Fagard RH, De Cort P. Orthostatic hypotension is a more robust predictor of 
cardiovascular events than nighttime reverse dipping in elderly. Hypertension. 2010;56(1):56-61. 
 
Fanciulli A, Strano S, Colosimo C, Caltagirone C, Spalletta G, Pontieri FE. The potential 
prognostic role of cardiovascular autonomic failure in alpha-synucleinopathies. Eur J Neurol. 
2013;20(2):231-5. 
 
A. Fanciulli - Cardiovascular autonomic failure in PD and MSA 
 
 
90 
Fanciulli A, Strano S, Ndayisaba JP, Goebel G, Gioffre L, Rizzo M, et al. Detecting nocturnal 
hypertension in Parkinson's disease and multiple system atrophy: proposal of a decision-support 
algorithm. J Neurol. 2014. 
 
Fanciulli A WG. Clinical presentation. In: Wenning G.K. FA, editor. Multiple system 
atrophy. Springer verlag; 2014. p. 97-119. 
 
Fedorowski A, Engstrom G, Hedblad B, Melander O. Orthostatic hypotension predicts 
incidence of heart failure: the Malmo preventive project. Am J Hypertens. 2010;23(11):1209-15. 
 
Fouad-Tarazi FM, Okabe M, Goren H. Alpha sympathomimetic treatment of autonomic 
insufficiency with orthostatic hypotension. Am J Med. 1995;99(6):604-10. 
 
Freeman R. Clinical practice. Neurogenic orthostatic hypotension. N Engl J Med. 
2008;358(6):615-24. 
 
Freeman R, Landsberg L, Young J. The treatment of neurogenic orthostatic hypotension 
with 3,4-DL-threo-dihydroxyphenylserine: a randomized, placebo-controlled, crossover trial. 
Neurology. 1999;53(9):2151-7. 
 
Freeman R, Wieling W, Axelrod FB, Benditt DG, Benarroch E, Biaggioni I, et al. Consensus 
statement on the definition of orthostatic hypotension, neurally mediated syncope and the 
postural tachycardia syndrome. Clin Auton Res. 2011;21(2):69-72. 
 
Gilman S, May SJ, Shults CW, Tanner CM, Kukull W, Lee VM, et al. The North American 
Multiple System Atrophy Study Group. J Neural Transm. 2005;112(12):1687-94. 
 
Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, et al. Second 
consensus statement on the diagnosis of multiple system atrophy. Neurology. 2008;71(9):670-6. 
 
Goldstein, editor. Adrenalin and the Inner World. An introduction to scientific integrative 
medicine: The John Hopkins University Press; 2006. 
 
Goldstein DS, Holmes C, Sharabi Y, Brentzel S, Eisenhofer G. Plasma levels of catechols and 
metanephrines in neurogenic orthostatic hypotension. Neurology. 2003;60(8):1327-32. 
 
Goldstein DS, Pechnik S, Holmes C, Eldadah B, Sharabi Y. Association between supine 
hypertension and orthostatic hypotension in autonomic failure. Hypertension. 2003;42(2):136-42. 
 
Goldstein IB, Bartzokis G, Guthrie D, Shapiro D. Ambulatory blood pressure and the brain: 
a 5-year follow-up. Neurology. 2005;64(11):1846-52. 
 
Gorell JM, Johnson CC, Rybicki BA. Parkinson's disease and its comorbid disorders: an 
analysis of Michigan mortality data, 1970 to 1990. Neurology. 1994;44(10):1865-8. 
 
Ha AD, Brown CH, York MK, Jankovic J. The prevalence of symptomatic orthostatic 
hypotension in patients with Parkinson's disease and atypical parkinsonism. Parkinsonism Relat 
Disord. 2011;17(8):625-8. 
 
Hohler AD, Zuzuarregui JR, Katz DI, Depiero TJ, Hehl CL, Leonard A, et al. Differences in 
motor and cognitive function in patients with Parkinson's disease with and without orthostatic 
hypotension. The International journal of neuroscience. 2012;122(5):233-6. 
A. Fanciulli - Cardiovascular autonomic failure in PD and MSA 
 
 
91 
 
Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ. What features improve the accuracy of 
clinical diagnosis in Parkinson's disease: a clinicopathologic study. 1992. Neurology. 2001;57(10 
Suppl 3):S34-8. 
 
Idiaquez J, Benarroch EE, Rosales H, Milla P, Rios L. Autonomic and cognitive dysfunction 
in Parkinson's disease. Clin Auton Res. 2007;17(2):93-8. 
 
Iqbal P, Stevenson L. Cardiovascular outcomes in patients with normal and abnormal 24-
hour ambulatory blood pressure monitoring. International journal of hypertension. 
2010;2011:786912. 
 
Jamnadas-Khoda J, Koshy S, Mathias CJ, Muthane UB, Ragothaman M, Dodaballapur SK. 
Are current recommendations to diagnose orthostatic hypotension in Parkinson's disease 
satisfactory? Mov Disord. 2009;24(12):1747-51. 
 
Jankovic J, Gilden JL, Hiner BC, Kaufmann H, Brown DC, Coghlan CH, et al. Neurogenic 
orthostatic hypotension: a double-blind, placebo-controlled study with midodrine. Am J Med. 
1993;95(1):38-48. 
 
Jecmenica-Lukic M, Poewe W, Tolosa E, Wenning GK. Premotor signs and symptoms of 
multiple system atrophy. Lancet Neurol. 2012;11(4):361-8. 
 
Jones JD, Jacobson C, Murphy M, Price C, Okun MS, Bowers D. Influence of hypertension 
on neurocognitive domains in nondemented Parkinson's disease patients. Parkinsons Dis. 
2014;2014:507529. 
 
Jordan J, Shannon JR, Biaggioni I, Norman R, Black BK, Robertson D. Contrasting actions of 
pressor agents in severe autonomic failure. Am J Med. 1998;105(2):116-24. 
 
Jordan J, Shannon JR, Pohar B, Paranjape SY, Robertson D, Robertson RM, et al. 
Contrasting effects of vasodilators on blood pressure and sodium balance in the hypertension of 
autonomic failure. J Am Soc Nephrol. 1999;10(1):35-42. 
 
Kaufmann H, Malamut R, Norcliffe-Kaufmann L, Rosa K, Freeman R. The Orthostatic 
Hypotension Questionnaire (OHQ): validation of a novel symptom assessment scale. Clin Auton 
Res. 2012;22(2):79-90. 
 
Kim JS, Oh YS, Lee KS, Kim YI, Yang DW, Goldstein DS. Association of cognitive dysfunction 
with neurocirculatory abnormalities in early Parkinson disease. Neurology. 2012;79(13):1323-31. 
 
Kitayama M, Wada-Isoe K, Irizawa Y, Nakashima K. Association of visual hallucinations 
with reduction of MIBG cardiac uptake in Parkinson's disease. J Neurol Sci. 2008;264(1-2):22-6. 
 
Kollensperger M, Geser F, Ndayisaba JP, Boesch S, Seppi K, Ostergaard K, et al. 
Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of 
the European multiple system atrophy registry. Mov Disord. 2010;25(15):2604-12. 
 
Kuo HK, Sorond F, Iloputaife I, Gagnon M, Milberg W, Lipsitz LA. Effect of blood pressure 
on cognitive functions in elderly persons. The journals of gerontology Series A, Biological sciences 
and medical sciences. 2004;59(11):1191-4. 
 
A. Fanciulli - Cardiovascular autonomic failure in PD and MSA 
 
 
92 
Lawrence GP, Home PD, Murray A. Repeatability of measurements and sources of 
variability in tests of cardiovascular autonomic function. British heart journal. 1992;68(2):205-11. 
 
Lim TS, Lee PH, Kim HS, Yong SW. White matter hyperintensities in patients with multiple 
system atrophy. J Neurol. 2009;256(10):1663-70. 
 
Low PA, Gilden JL, Freeman R, Sheng KN, McElligott MA. Efficacy of midodrine vs placebo 
in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine 
Study Group. JAMA. 1997;277(13):1046-51. 
 
Luukinen H, Koski K, Laippala P, Airaksinen KE. Orthostatic hypotension and the risk of 
myocardial infarction in the home-dwelling elderly. Journal of internal medicine. 2004;255(4):486-
93. 
 
Ma JF, Sun JL, Zhao J, Wei X, Wang BS, Fu Y. Relationship between nocturnal blood 
pressure variation and silent cerebral infarction in Chinese hypertensive patients. J Neurol Sci. 
2010;294(1-2):67-9. 
 
Masaki KH, Schatz IJ, Burchfiel CM, Sharp DS, Chiu D, Foley D, et al. Orthostatic 
hypotension predicts mortality in elderly men: the Honolulu Heart Program. Circulation. 
1998;98(21):2290-5. 
 
Matinolli M, Korpelainen JT, Korpelainen R, Sotaniemi KA, Myllyla VV. Orthostatic 
hypotension, balance and falls in Parkinson's disease. Mov Disord. 2009;24(5):745-51. 
 
Matsubayashi K, Okumiya K, Wada T, Osaki Y, Fujisawa M, Doi Y, et al. Postural 
dysregulation in systolic blood pressure is associated with worsened scoring on neurobehavioral 
function tests and leukoaraiosis in the older elderly living in a community. Stroke. 
1997;28(11):2169-73. 
 
Maule S, Milan A, Grosso T, Veglio F. Left ventricular hypertrophy in patients with 
autonomic failure. Am J Hypertens. 2006;19(10):1049-54. 
 
Maule S, Milazzo V, Maule MM, Di Stefano C, Milan A, Veglio F. Mortality and prognosis in 
patients with neurogenic orthostatic hypotension. Funct Neurol. 2012;27(2):101-6. 
 
Mehrabian S, Duron E, Labouree F, Rollot F, Bune A, Traykov L, et al. Relationship between 
orthostatic hypotension and cognitive impairment in the elderly. J Neurol Sci. 2010;299(1-2):45-8. 
 
Mostile G, Jankovic J. Treatment of dysautonomia associated with Parkinson's disease. 
Parkinsonism Relat Disord. 2009;15 Suppl 3:S224-32. 
 
Murray AD, Staff RT, Shenkin SD, Deary IJ, Starr JM, Whalley LJ. Brain white matter 
hyperintensities: relative importance of vascular risk factors in nondemented elderly people. 
Radiology. 2005;237(1):251-7. 
 
O'Sullivan SS, Massey LA, Williams DR, Silveira-Moriyama L, Kempster PA, Holton JL, et al. 
Clinical outcomes of progressive supranuclear palsy and multiple system atrophy. Brain. 
2008;131(Pt 5):1362-72. 
 
Oh YS, Kim JS, Lee KS. Orthostatic and supine blood pressures are associated with white 
matter hyperintensities in Parkinson disease. Journal of movement disorders. 2013;6(2):23-7. 
 
A. Fanciulli - Cardiovascular autonomic failure in PD and MSA 
 
 
93 
Orimo S, Uchihara T, Nakamura A, Mori F, Kakita A, Wakabayashi K, et al. Axonal alpha-
synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's 
disease. Brain. 2008;131(Pt 3):642-50. 
 
Papp MI, Lantos PL. The distribution of oligodendroglial inclusions in multiple system 
atrophy and its relevance to clinical symptomatology. Brain. 1994;117 ( Pt 2):235-43. 
 
Peralta C, Stampfer-Kountchev M, Karner E, Kollensperger M, Geser F, Wolf E, et al. 
Orthostatic hypotension and attention in Parkinson's disease with and without dementia. J Neural 
Transm. 2007;114(5):585-8. 
 
Perera R, Isola L, Kaufmann H. Effect of recombinant erythropoietin on anemia and 
orthostatic hypotension in primary autonomic failure. Clin Auton Res. 1995;5(4):211-3. 
 
Petrovic IN, Ling H, Asi Y, Ahmed Z, Kukkle PL, Hazrati LN, et al. Multiple system atrophy-
parkinsonism with slow progression and prolonged survival: a diagnostic catch. Mov Disord. 
2012;27(9):1186-90. 
 
Pilleri M, Facchini S, Gasparoli E, Biundo R, Bernardi L, Marchetti M, et al. Cognitive and 
MRI correlates of orthostatic hypotension in Parkinson's disease. J Neurol. 2013;260(1):253-9. 
 
Plaschke M, Trenkwalder P, Dahlheim H, Lechner C, Trenkwalder C. Twenty-four-hour 
blood pressure profile and blood pressure responses to head-up tilt tests in Parkinson's disease 
and multiple system atrophy. J Hypertens. 1998;16(10):1433-41. 
 
Podoleanu C, Maggi R, Brignole M, Croci F, Incze A, Solano A, et al. Lower limb and 
abdominal compression bandages prevent progressive orthostatic hypotension in elderly persons: 
a randomized single-blind controlled study. J Am Coll Cardiol. 2006;48(7):1425-32. 
 
Poewe W. Dysautonomia and cognitive dysfunction in Parkinson's disease. Mov Disord. 
2007;22 Suppl 17:S374-8. 
 
Rose KM, Couper D, Eigenbrodt ML, Mosley TH, Sharrett AR, Gottesman RF. Orthostatic 
hypotension and cognitive function: the Atherosclerosis Risk in Communities Study. 
Neuroepidemiology. 2010;34(1):1-7. 
 
Rose KM, Eigenbrodt ML, Biga RL, Couper DJ, Light KC, Sharrett AR, et al. Orthostatic 
hypotension predicts mortality in middle-aged adults: the Atherosclerosis Risk In Communities 
(ARIC) Study. Circulation. 2006;114(7):630-6. 
 
Rose KM, Holme I, Light KC, Sharrett AR, Tyroler HA, Heiss G. Association between the 
blood pressure response to a change in posture and the 6-year incidence of hypertension: 
prospective findings from the ARIC study. Journal of human hypertension. 2002;16(11):771-7. 
 
Rose KM, Tyroler HA, Nardo CJ, Arnett DK, Light KC, Rosamond W, et al. Orthostatic 
hypotension and the incidence of coronary heart disease: the Atherosclerosis Risk in Communities 
study. Am J Hypertens. 2000;13(6 Pt 1):571-8. 
 
Sakakibara R, Hattori T, Uchiyama T, Kita K, Asahina M, Suzuki A, et al. Urinary dysfunction 
and orthostatic hypotension in multiple system atrophy: which is the more common and earlier 
manifestation? J Neurol Neurosurg Psychiatry. 2000;68(1):65-9. 
 
A. Fanciulli - Cardiovascular autonomic failure in PD and MSA 
 
 
94 
Sakakibara R, Matsuda S, Uchiyama T, Yoshiyama M, Yamanishi T, Hattori T. The effect of 
intranasal desmopressin on nocturnal waking in urination in multiple system atrophy patients 
with nocturnal polyuria. Clin Auton Res. 2003;13(2):106-8. 
 
Schmidt C, Berg D, Prieur S, Junghanns S, Schweitzer K, Globas C, et al. Loss of nocturnal 
blood pressure fall in various extrapyramidal syndromes. Mov Disord. 2009;24(14):2136-42. 
 
Schrag A, Geser F, Stampfer-Kountchev M, Seppi K, Sawires M, Kollensperger M, et al. 
Health-related quality of life in multiple system atrophy. Mov Disord. 2006;21(6):809-15. 
Schutzman J, Jaeger F, Maloney J, Fouad-Tarazi F. Head-up tilt and hemodynamic changes during 
orthostatic hypotension in patients with supine hypertension. J Am Coll Cardiol. 1994;24(2):454-
61. 
 
Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox SH, Katzenschlager R, et al. The 
Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-
motor symptoms of Parkinson's disease. Mov Disord. 2011;26 Suppl 3:S42-80. 
 
Shannon J, Jordan J, Costa F, Robertson RM, Biaggioni I. The hypertension of autonomic 
failure and its treatment. Hypertension. 1997;30(5):1062-7. 
 
Shy GM, Drager GA. A neurological syndrome associated with orthostatic hypotension: a 
clinical-pathologic study. Arch Neurol. 1960;2:511-27. 
 
Singer W, Opfer-Gehrking TL, McPhee BR, Hilz MJ, Bharucha AE, Low PA. 
Acetylcholinesterase inhibition: a novel approach in the treatment of neurogenic orthostatic 
hypotension. J Neurol Neurosurg Psychiatry. 2003;74(9):1294-8. 
 
Smit AA, Wieling W, Fujimura J, Denq JC, Opfer-Gehrking TL, Akarriou M, et al. Use of 
lower abdominal compression to combat orthostatic hypotension in patients with autonomic 
dysfunction. Clin Auton Res. 2004;14(3):167-75. 
 
Staessen JA, Asmar R, De Buyzere M, Imai Y, Parati G, Shimada K, et al. Task Force II: blood 
pressure measurement and cardiovascular outcome. Blood Press Monit. 2001;6(6):355-70. 
 
Stubendorff K, Aarsland D, Minthon L, Londos E. The impact of autonomic dysfunction on 
survival in patients with dementia with lewy bodies and Parkinson's disease with dementia. PLoS 
One. 2012;7(10):e45451. 
 
Tada M, Onodera O, Ozawa T, Piao YS, Kakita A, Takahashi H, et al. Early development of 
autonomic dysfunction may predict poor prognosis in patients with multiple system atrophy. Arch 
Neurol. 2007;64(2):256-60. 
 
Tanaka H, Yamaguchi H, Tamai H. Treatment of orthostatic intolerance with inflatable 
abdominal band. Lancet. 1997;349(9046):175. 
 
Tha KK, Terae S, Yabe I, Miyamoto T, Soma H, Zaitsu Y, et al. Microstructural white matter 
abnormalities of multiple system atrophy: in vivo topographic illustration by using diffusion-tensor 
MR imaging. Radiology. 2010;255(2):563-9. 
 
Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa 
dose equivalency reporting in Parkinson's disease. Mov Disord. 2010;25(15):2649-53. 
 
A. Fanciulli - Cardiovascular autonomic failure in PD and MSA 
 
 
95 
Vagaonescu TD, Saadia D, Tuhrim S, Phillips RA, Kaufmann H. Hypertensive cardiovascular 
damage in patients with primary autonomic failure. Lancet. 2000;355(9205):725-6. 
 
Vanacore N, Bonifati V, Fabbrini G, Colosimo C, Marconi R, Nicholl D, et al. Smoking habits 
in multiple system atrophy and progressive supranuclear palsy. European Study Group on Atypical 
Parkinsonisms. Neurology. 2000;54(1):114-9. 
 
Velseboer DC, de Haan RJ, Wieling W, Goldstein DS, de Bie RM. Prevalence of orthostatic 
hypotension in Parkinson's disease: a systematic review and meta-analysis. Parkinsonism Relat 
Disord. 2011;17(10):724-9. 
 
Verghese J, Lipton RB, Hall CB, Kuslansky G, Katz MJ. Low blood pressure and the risk of 
dementia in very old individuals. Neurology. 2003;61(12):1667-72. 
 
Viramo P, Luukinen H, Koski K, Laippala P, Sulkava R, Kivela SL. Orthostatic hypotension 
and cognitive decline in older people. J Am Geriatr Soc. 1999;47(5):600-4. 
 
Watanabe H, Saito Y, Terao S, Ando T, Kachi T, Mukai E, et al. Progression and prognosis in 
multiple system atrophy: an analysis of 230 Japanese patients. Brain. 2002;125(Pt 5):1070-83. 
 
Wenning GF, A. Dysautonomia in Movement Disorders. In: J PWaJ, editor. Movement 
Disorders in neurologic and Systemic Disease: Cambridge Uni Press; 2013. 
 
Wenning GK, Granata R, Krismer F, Durr S, Seppi K, Poewe W, et al. Orthostatic 
hypotension is differentially associated with the cerebellar versus the parkinsonian variant of 
multiple system atrophy: a comparative study. Cerebellum. 2012;11(1):223-6. 
 
Wenning GK, Tison F, Ben Shlomo Y, Daniel SE, Quinn NP. Multiple system atrophy: a 
review of 203 pathologically proven cases. Mov Disord. 1997;12(2):133-47. 
 
Wright RA, Kaufmann HC, Perera R, Opfer-Gehrking TL, McElligott MA, Sheng KN, et al. A 
double-blind, dose-response study of midodrine in neurogenic orthostatic hypotension. 
Neurology. 1998;51(1):120-4. 
 
Yano Y, Inokuchi T, Hoshide S, Kanemaru Y, Shimada K, Kario K. Association of poor 
physical function and cognitive dysfunction with high nocturnal blood pressure level in treated 
elderly hypertensive patients. Am J Hypertens. 2011;24(3):285-91. 
 
Yap PL, Niti M, Yap KB, Ng TP. Orthostatic hypotension, hypotension and cognitive status: 
early comorbid markers of primary dementia? Dementia and geriatric cognitive disorders. 
2008;26(3):239-46. 
 
